



US005686257A

# United States Patent [19]

Kennedy et al.

[11] Patent Number: **5,686,257**

[45] Date of Patent: **Nov. 11, 1997**

[54] **BINDING COMPOSITIONS FOR MAMMALIAN T CELL ANTIGENS AND RELATED REAGENTS**

[75] Inventors: **Jacqueline Kennedy, Sunnyvale; J. Fernando Bazan, Menlo Park; Albert Zlotnik, Palo Alto, all of Calif.**

[73] Assignee: **Schering Corporation, Kenilworth, N.J.**

[21] Appl. No.: **429,742**

[22] Filed: **Apr. 26, 1995**

[51] Int. Cl.<sup>6</sup> ..... **C07K 16/00; C07K 17/00; C07K 17/14; C07K 1/00**

[52] U.S. Cl. .... **435/7.24; 435/7.5; 436/518; 530/387.9; 530/388.1; 530/388.75; 530/389.6; 530/391.1; 530/391.7; 530/402; 530/413**

[58] Field of Search ..... **530/387.9, 391.7, 530/413, 402, 388.1, 388.75, 389.6, 391.1; 424/144.1, 134.1, 181.1, 183.1; 435/7.24, 7.5, 7.92, 7.94, 975, 810; 436/518**

[56] **References Cited**

**U.S. PATENT DOCUMENTS**

4,376,110 3/1983 David et al. .... 436/513  
5,167,956 12/1992 Neville, Jr. .... 424/85.91

**OTHER PUBLICATIONS**

Tan, P. H. S. *J. of Immunol.* 150: 812-820. Feb. 1, 1993.  
Sandmaier, B. M. et al. *Blood* 76: 630-635. Aug. 1, 1990.  
Mackay, C. R. et al. *J. of Cell Biology* 124: 71-82. Jan. 1994.

Seaver, S. *Genetic Engineering News*, vol. 14, pp. 10 and 21 Aug. 14, 1994.

Hisashi Arase, et al. "Cytotoxicity of Fresh NK1.1<sup>+</sup>T Cell Receptor  $\alpha/\beta$ <sup>+</sup>Thymocytes against a CD4<sup>+</sup>8<sup>+</sup>Thymocyte Population Associated with Intact Fas Antigen Expression on the Target," *J. Exp. Med.* 180:423-432, Aug. 1994.

William E. Paul (ed.) *Fundamental Immunology*, Raven Press, New York, Third Edition, title page, verso, and table of contents, 1993.

Wayne M. Yokoyama "the Ly-49 and NKR-P1 Gene Families Encoding Lectin-like Receptors on Natural Killer Cells: The NK Gene Complex," *Annu. Rev. Immunol.* 11:613-625, 1993.

Albert Zlotnik, et al. "Cytokine Production by Mature and Immature CD4<sup>+</sup>8<sup>+</sup>T Cells," *J. Immunol.* 149:1211-1215, Aug. 1992.

Kelner, et al., *Science*, 266: 1395-1399 (25 Nov. 1994) "Lymphotoxin: A Cytokine That Represents a New Class of Chemokine".

Zlotnik, et al., *The FASEB Journal*, 10(6): A1037, Abr. No. 216 (Jun. 1996) "Molecular Characterization of NK+T cells and cloning of CRTAM".

*Primary Examiner*—Christina Y. Chan

*Assistant Examiner*—Evelyn Rabin

*Attorney, Agent, or Firm*—Sheela Mohan-Peterson; Edwin P. Ching

[57] **ABSTRACT**

T cell surface antigens from mammals, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said antigens. Methods of using said reagents and diagnostic kits are also provided.

**28 Claims, No Drawings**

## BINDING COMPOSITIONS FOR MAMMALIAN T CELL ANTIGENS AND RELATED REAGENTS

### FIELD OF THE INVENTION

The present invention relates to compositions related to proteins which function in controlling physiology, development, and differentiation of mammalian cells, e.g., cells of a mammalian immune system. In particular, it provides proteins and mimetics which regulate cellular physiology, development, differentiation, or function of various cell types, including hematopoietic cells, and particularly T cell progenitors.

### BACKGROUND OF THE INVENTION

The immune system of vertebrates consists of a number of organs and several different cell types. Two major cell types include the myeloid and lymphoid lineages. Among the lymphoid cell lineage are B cells, which were originally characterized as differentiating in fetal liver or adult bone marrow, T cells, which were originally characterized as differentiating in the thymus, and natural killer (NK) cells. See, e.g., Paul (ed.) (1994) *Fundamental Immunology* (3d ed.) Raven Press, New York.

In many aspects of the development of an immune response or cellular differentiation, soluble proteins, e.g., cytokines, and cell surface antigens, e.g., CD markers, play critical roles in regulating cellular interactions. These cytokines and cell markers mediate cellular activities in many ways. They have been shown, in many cases, to modulate proliferation, growth, and differentiation of hematopoietic stem cells into the vast number of progenitors composing the lineages responsible for an immune response.

However, the cellular molecules which are expressed by different developmental stages of cells in these maturation pathways are still incompletely identified. Moreover, the roles and mechanisms of action of signaling molecules which induce, sustain, or modulate the various physiological, developmental, or proliferative states of these cells is poorly understood. Clearly, the immune system and its response to various stresses have relevance to medicine, e.g., infectious diseases, cancer related responses and treatment, allergic and transplantation rejection responses. See, e.g., Thorn et al. *Harrison's Principles of Internal Medicine* McGraw/Hill, New York.

Medical science relies, in large degree, to appropriate recruitment or suppression of the immune system in effecting cures for insufficient or improper physiological responses to environmental factors. However, the lack of understanding of how the immune system is regulated or differentiates has blocked the ability to advantageously modulate the normal defensive mechanisms to biological challenges. Medical conditions characterized by abnormal or inappropriate regulation of the development or physiology of relevant cells thus remain unmanageable. The discovery and characterization of specific cytokines and markers, e.g., involved in cell-cell interactions, will contribute to the development of therapies for a broad range of degenerative or other conditions which affect the immune system, hematopoietic cells, as well as other cell types. The present invention provides solutions to some of these and many other problems.

### SUMMARY OF THE INVENTION

The present invention is based, in part, upon the discovery of a cDNA clone encoding a member of a family of cell

surface markers, initially characterized on early T cell progenitors and designated Cytotoxic or Regulatory T cell Associated Molecule (CRTAM). The invention embraces isolated genes encoding the proteins of the invention, variants of the encoded proteins, e.g., mutations (muteins) of the natural sequence, species and allelic variants, fusion proteins, chemical mimetics, antibodies, and other structural or functional analogues. Various uses of these different nucleic acid or protein compositions are also provided.

The present invention provides nucleic acids encoding a CRTAM protein or fragment thereof; a substantially pure CRTAM or peptide thereof, or a fusion protein comprising CRTAM sequence; and an antibody to a CRTAM protein.

In nucleic acid embodiments, the nucleic acid can comprise a sequence of Table 3.

In substantially pure CRTAM protein or peptide thereof embodiments, the protein or peptide can be from a primate, including a human; comprise at least one polypeptide segment of Table 3; or exhibit a post-translational modification pattern distinct from natural CRTAM protein. A further embodiment is a composition comprising such a protein and a pharmaceutically acceptable carrier.

In antibody embodiments, the antigen can be a primate protein, including a human; the antibody is raised against a protein sequence of Table 3; the antibody is a monoclonal antibody; or the antibody is labeled.

The invention also embraces a kit comprising a substantially pure nucleic acid encoding a CRTAM protein or peptide; a substantially pure CRTAM protein or fragment, e.g., as a positive control; or an antibody or receptor which specifically binds a CRTAM protein.

Methods for screening for ligands or other proteins which specifically bind to CRTAM are also provided.

The availability of these reagents also provides methods of modulating physiology or development of a cell comprising contacting said cell with an agonist or antagonist of a CRTAM protein. For example, the antagonist might be an antibody against a mammalian CRTAM protein or the cell may be a hematopoietic cell, including a lymphoid cell.

### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

#### Outline

- I. General
- II. Nucleic Acids
  - A. natural isolates; methods
  - B. synthetic genes
  - C. methods to isolate
- III. Purified CRTAM protein
  - A. physical properties
  - B. biological properties
- IV. Making CRTAM protein; Mimetics
  - A. recombinant methods
  - B. synthetic methods
  - C. natural purification
- V. Physical Variants
  - A. sequence variants, fragments
  - B. post-translational variants
    1. glycosylation
    2. others
- VI. Functional Variants
  - A. analogues; fragments
    1. agonists
    2. antagonists



TABLE 3-continued

Nucleotide sequence encoding a human CRTAM protein and predicted amino acid sequence. Also can use complementary nucleic acid sequences for many purposes. Designated SEQ ID NO: 1 and 2.	
359 aaggaagtgaagtgattgtgctggcaactccttcaagccaatcctggaagctcagtt	418
108 LysGluValLysValIleValLeuAlaThrProPheLysProIleLeuGluAlaSerVal	127
419 atcagaagcaaaatggagaagaacatgtgtactcatgtctccaccatgagaagcaag	478
128 IleArgLysGlnAsnGlyGluGluHisValValLeuMETCysSerThrMETArgSerLys	147
479 cccctccgcagataacctggctactgggaatagcatggaagtgtccggggaacgctc	538
148 ProProProGlnIleThrTrpLeuLeuGlyAsnSerMETGluValSerGlyGlyThrLeu	167
539 catgaattgaaactgatgggaagaaatgtaatactaccagcacttcataatcctctct	598
168 HisGluPheGluThrAspGlyLysLysCysAsnThrThrSerThrLeuIleIleLeuSer	187
599 tatggcaaaaattcaacgggtgactgcattatccgacacagagcctgcaaggagaaaa	658
188 TyrGlyLysAsnSerThrValAspCysIleIleArgHisArgGlyLeuGlnGlyArgLys	207
659 ctagttagcaccctccggttgaagaTTTGGTTACTGATGAAGAGACAGCTTCAGATGCT	718
208 LeuValAlaProPheArgPheGluAspLeuValThrAspGluGluThrAlaSerAspAla	227
719 CTGGAGAGAAACTCTCTATCCACACAAGACCCACAGCAGCCCACCAGTACTGTCTCAGTa	778
228 LeuGluArgAsnSerLeuSerThrGlnAspProGlnGlnProThrSerThrValSerVal	247
779 ACGGAAGATTCTAGTACTtcggagattgacaaggagaagaagaacaaccactcaagat	838
248 ThrGluAspSerSerThrSerGluIleAspLysGluGluLysGluGlnThrThrGlnAsp	267
839 cctgacttgaccaccgaagcaaatcctcagatttaggactggcaagaagaaaaatggc	898
268 ProAspLeuThrThrGluAlaAsnProGlnTyrLeuGlyLeuAlaArgLysLysSerGly	287
898 atcctgctgctcagctgggtgctctctcatttcatactctcatatagtcagctc	958
288 IleLeuLeuLeuThrLeuValSerPheLeuIlePheIleLeuPheIleIleValGlnLeu	307
959 ttcatcatgaagctgaggaagacacatgtgatatggaagagagaaaacgaagttcagaa	1018
308 PheIleMETLysLeuArgLysAlaHisValIleTrpLysArgGluAsnGluValSerGlu	327
1019 cacacactagaaagttacagatcaaggTCAAATAATGAAGAAACATCATCTGAAGAGAAA	1078
328 HisThrLeuGluSerTyrArgSerArgSerAsnAsnGluGluThrSerSerGluGluLys	347
1079 AATGGCCAATCTTCCCTCCCTATGCGTTGCATGAACACTACATCACAAAGTTGTACTCAGAA	1138
348 AsnGlyGlnSerSerLeuProMETArgCysMETAsnTyrIleThrLysLeuTyrSerGlu	367
1139 GCAAAAACAAAAGAGGAAGGAAAATGTACAACATTCAAAATTAGAAGAAAAGCACATCCAA	1198
368 AlaLysThrLysArgLysGluAsnValGlnHisSerLysLeuGluGluLysHisIleGln	387
1199 GTACCAGAGAGTATTGTGTAG TGCTCTCTGC AATGGAACAT GTGATTTTCAG	1249
388 ValProGluSerIleVal	393
1250 GGTTCGCCGA GTGTCACCTC AGTGGACCAG CCTGGGGGAA GGAGCTTAAT TGCTGAGACA	1309
1310 TThaataatga cctcttagtg caatgcaaga tgggtgctc ggataatgat ctgccccgga	1369
1370 gctagggcag caaatgagg accaaacat gcacataaag ctgtagttt aaaaaagaaa	1429
1430 agcaaaaaaa taattatgcc tgacactact tcagagcagg aggatctac gaagccttg	1489
1490 ggatcagggt cagtgtgagc agctaacatc ctacctcaa tggaaacagga tttttgatG	1549
1550 Cttgctcta atggaactgt tttAaaaatt ttttttctt ttaaatatt tcttctggtc	1609
1610 acaaaataaa gaaatttggg atgcaagta cctaaagatc tctgaccta agaagtact	1669
1670 tctggccagg cgcggtgct catgcctgta atcctagcac tttgggagc tgaggtagc	1729
1730 agatcactg agtcaggag ttggagacca gctggccaa catagtgaaa cccgctct	1789
1790 actaaaaatg caaaaattag ccaggcgtag tggcgccac ctgtagtctc agatactgg	1849
1850 gaggctgagg gtggagaatc gctgaacct gggaggtgga gattgcagt agtcaagatc	1909
1910 tcaccactga actccagcct gggcgacaga gggagactct gtctcaaaaa aaaagaagt	1969
1970 acttcaaga cagacttta acatgtaacc agcacaagc aaTGTCAGGG AGGAGTGATA	2029
2030 CATGACAATA AATGAGTCAG ATGAGCAAGA AGGCCCCAGA ACCCATGCC CAAGGCACAA	2089
2090 AGAGGAGCTC AGGGTAGGCC CAAAGACTCG AATTCCTTAG ATACTAAAT CACATGAGCG	2149

TABLE 3-continued

Nucleotide sequence encoding a human CRTAM protein and predicted amino acid sequence. Also can use complementary nucleic acid sequences for many purposes. Designated SEQ ID NO: 1 and 2.		
2150	GACCTTGCT GTCAGATAAG ATTTTACCT GGAAATCCA TGACCAATAC ATGTGCAAAA	2209
2210	GAAAATGATC GGTGAATTT ACTGATTATT gacctaagtg atggctttt AAaatgttt	2269
2270	aataaaaaag cagaatagat gttgtttt ctagtggtta taccaagta tacttcctgt	2329
2330	ttcacgtgt gaaagtaaca tgggacatgc ctctcttc cgaicagttt atttaagcta	2389
2390	tacagcaaac ttggcattt atgtggagca ttctcattg ttggaatctg aataaaccaa	2449
2450	ttacaaata aaaaaaaaa aaaaaaa	2477

The mouse sequence provided here contains sequence corresponding to recognition sites for the following restriction enzymes (see Manufacturers' catalogs from, e.g., Boehringer, Gibco-BRL, New England Biolabs, U.S. Biochemicals, and GCG Sequence Analysis Package restriction site lists): AccI; AccII; AflII; AflIII; AluI; AlwI; AlwNI; ApaLI; AsuI; AvaI; AvaII; BanI; BanII; BbvI; BcnI; BglI; BglII; BspHI; BstUI; Cfr10I; DdeI; DpnI; DraI; DraII;

DraIII; EcoRII; EspI; Fnu4HI; FokI; HaeIII; HgiAI; HhaI; HindII; HindIII; HinfI; HpaII; HphI; MaeI; MaeII; MaeIII; MboI; MboII; MnlI; MseI; NciI; NcoI; NlaIII; NlaIV; Nsp-BII; NspI; PfiMI; PleI; PvuII; RsaI; SacI; ScaI; ScrFI; SduI; SfaNI; SphI; StuI; StyI; TaqI; ThaI; Tth111I; XbaI; and XhoII.

The coding sequence runs from nucleotide positions 31 to 1197. See Table 4.

TABLE 4

Nucleotide sequence encoding a mouse CRTAM protein and predicted amino acid sequence. Also can use complementary nucleic acid sequences for many purposes. Designated SEQ ID NO: 3 and 4.		
1	ggaaagctcc ctccgttcag cacagccagc atgtgtggggagtccctcagttgctg	57
	METTrpTrpGlyValLeuSerLeuLeu	9
58	ttctgggtgccgtgcaagcagcctttctgaaaatggagaccgtcacggtagaggaagc	117
10	PheTrpValProValGlnAlaAlaPheLeuLysMETGluThrValThrValGluGluGly	29
118	caaacgtcactctaactgtgttactctcagacaaaaaacgtctctccagtggtc	177
30	GlnThrLeuThrLeuThrCysValThrSerGlnThrLysAsnValSerLeuGlnTrpLeu	49
178	gtccctctgggtcaccatttttaaccagcctcctcttaaaaagctccaatac	237
50	AlaProSerGlyPheThrIlePheLeuAsnGlnHisProAlaLeuLysSerSerLysTyr	69
238	cagttctcaccattcagctacacaactctcattagtggtccaatgtaactctcca	297
70	GlnLeuLeuHisHisSerAlaThrGlnLeuSerIleSerValSerAsnValThrLeuArg	89
298	gaggaaggtgtatatacattctgactacgggagttctgtgaagacgaagcaagtga	357
90	GluGluGlyValTyrThrCysLeuHisTyrGlySerSerValLysThrLysGlnValArg	109
358	gtgaccgtgttagtgactcttccagccaaccgtggaagctttgttctcagaaggcag	417
110	ValThrValLeuValThrProPheGlnProThrValGluAlaLeuValLeuArgGln	129
418	aatggagagaatctgtgtgctgaaatgtccacagagagaagcaagccccgccaaa	477
130	AsnGlyGluLysSerValValLeuLysCysSerThrGluArgSerLysProProGln	149
478	atcacctgctgctggggaaggtctggagatctatgtgactccaccatgaattgaa	537
169	IleThrTrpLeuLeuGlyGluGlyLeuGluLeuTyrGlyGluLeuHisHisGluPheGlu	169
538	gctgatgggaaaatgtaaccagcagcagcgtcctcgtcccgccgtagcgaacaa	597
170	AlaAspGlyLysIleCysAsnThrSerSerThrLeuIleAlaArgAlaTyrGlyLysAsn	189
598	tcaaccgtcactgcattatccagcagcagggcttgcacggagaaagctggtgccccc	657
190	SerThrValHisCysIleIleGlnHisGluGlyLeuHisGlyArgLysLeuValAlaPro	209
658	ttccagttgaagattggtgcagatcaagaacgacttcagatgccctgagcagagc	717
210	PheGlnPheGluAspLeuValAlaAspGlnGluThrThrSerAspAlaProGluGlnSer	229
718	tcctctctcccaagccctccagcagcccaagtagctcattatgatggaattcc	777
230	SerLeuSerSerGlnAlaLeuGlnGlnProThrSerThrValSerMETMETGluAsnSer	249
778	agtataccagagactgacaaggaagagaagaacatgacctcaagacctgctgtcc	837
250	SerIleProGluThrAspLysGluGluLysGluHisAlaThrGlnAspProGlyLeuSer	269
838	actgccagtctcagcatacaggactgcccggaggaagagtgtatcctgctcagc	897
270	ThrAlaSerAlaGlnHisThrGlyLeuAlaArgArgLysSerGlyIleLeuLeuThr	289
898	ctgtgtctctctcatttcatcttctcctcctcctcctcctcctcctcctcctcctc	957
290	LeuValSerPheLeuIlePheIleLeuPheIleIleValGlnLeuPheIleMETLysLeu	309
958	cgtaaagcacacgtggtatggaagaaggaaggtgaaattcagagcaagcTCTAGAAAGT	1017
310	ArgLysAlaHisValValTrpLysLysGluSerGluIleSerGluGlnAlaLeuGluSer	329
1018	TACAGATCAAGATCCAACAACGAGGAGACATCTTCCCAGGAGAAATAGCAGCCAGGCTCCC	1077
330	TyrArgSerArgSerAsnAsnGluGluThrSerSerGlnGluAsnSerGlnAlaPro	349
1078	CAGTCTAAGCGTTGCACTGAACTACATCACGCGATTATCTCGGAGCCAAAACAAGAAG	1137
350	GlnSerLysArgCysMETAsnTyrIleThrGlnLeuTyrSerGlyAlaLysThrLysLys	369
1138	AGTGCCAGCACTGGAAGCTCGGAGGCAAGCACAGCCGTGTCCCGGAGAGTATTGTGTAG	1197
370	SerAlaGlnHisTrpLysLeuGlyGlyLysHisSerArgValProGluSerIleVal	389
1198	TGTTCCCTGC AATAGAAGAT AGGATTTTCCAG GGCAGCCGCA TCAGGCCCTG GAAAGGATCG	1257
1258	TAAGTACTGT GACATGAAAA AAATAGAATG TCCATTGAGT ACAATTCAAG ACAGTGTCCA	1317

TABLE 4-continued

Nucleotide sequence encoding a mouse CRTAM protein and predicted amino acid sequence. Also can use complementary nucleic acid sequences for many purposes. Designated SEQ ID NO: 3 and 4.

1318	TTGAGCCAGG GCAGCCACAT GAGGACCAAG CCATGGACAG AAAGCTCCTC GCTGAAAGGA	1377
1378	AAACATAGAA AGAACCTATT ATGACTGACA CTACCTCAGA GCTGGAGAAC TCTGCTAAGT	1437
1438	CGTTTTGGAT CAGGGTCAA ATGACCAGTG AGCAGCTGAC CTCGAAGGGA ACAGCTTTTT	1497
1498	AGACCTGGGG CTGGAGTGGG ACTGTTTGAA TTGGTTTAAA ATCTTTCCTT CTCGGTCAAG	1557
1558	AAGAACTTAA GCAGAGAAGT ACCCCAAGGA GACCTGAGAT GCCAGCAGCC TGCTTTCAAG	1617
1618	ACAGCCTCTC AGAAGAGGCC TGGTgggcaa cagagaaatg tgggctgtta cagcacacag	1677
1678	tgaacatgat gctcccAGA GAGCTACAAC TCTCAACTGA GTTCAACTGA CAAGAGGCTT	1737
1738	CCTGACTAAC CATGAGCCAA CCTGACAGGC CACTTTTATC CTAATTACAC CATGGTAAAA	1797
1798	GTAGGGACAG AAGCAAAGT TGAGTTTGGT TGACAGACTG TTGAATTTGT GACTGGCTTT	1857
1858	TAGAATTTA ATAAAGACCA GAATGTGTCT TTTAGAGGC TGTCATGCC ATTGATAAAA	1917
1918	AAAAAAAAA AAAAAAAAAA AAA	1940

The purified protein or defined peptides are useful for generating antibodies by standard methods, as described above. Synthetic peptides or purified protein can be presented to an immune system to generate a specific binding composition, e.g., monoclonal or polyclonal antibodies. See, e.g., Coligan (1991) *Current Protocols in Immunology* Wiley/Greene; and Harlow and Lane (1989) *Antibodies: A Laboratory Manual* Cold Spring Harbor Press.

For example, the specific binding composition could be used for screening of an expression library made from a cell line which expresses a CRTAM protein. The screening can be standard staining of surface expressed protein, or by panning. Screening of intracellular expression can also be performed by various staining or immunofluorescence procedures. The binding compositions could be used to affinity purify or sort out cells expressing the protein.

This invention contemplates use of isolated DNA or fragments to encode a biologically active CRTAM protein or polypeptide. In addition, this invention covers isolated or recombinant DNA which encodes a biologically active protein or polypeptide and which is capable of hybridizing under appropriate conditions with the DNA sequences described herein. Said biologically active protein or polypeptide can be an intact antigen, or fragment, and have an amino acid sequence as disclosed in Table 3 or 4. Further, this invention covers the use of isolated or recombinant DNA, or fragments thereof, which encode proteins which are homologous to a CRTAM protein or which were isolated using cDNA encoding a CRTAM protein as a probe. The isolated DNA can have the respective regulatory sequences in the 5' and 3' flanks, e.g., promoters, enhancers, poly-A addition signals, and others.

An "isolated" nucleic acid is a nucleic acid, e.g., an RNA, DNA, or a mixed polymer, which is substantially separated from other components which naturally accompany a native sequence, e.g., ribosomes, polymerases, and flanking genomic sequences from the originating species. The term embraces a nucleic acid sequence which has been removed from its naturally occurring environment, and includes recombinant or cloned DNA isolates and chemically synthesized analogues or analogues biologically synthesized by heterologous systems. A substantially pure molecule includes isolated forms of the molecule. Alternatively, a purified species may be separated from host components from a recombinant expression system.

An isolated nucleic acid will generally be a homogeneous composition of molecules, but will, in some embodiments, contain minor heterogeneity. This heterogeneity is typically found at the polymer ends or portions not critical to a desired biological function or activity.

A "recombinant" nucleic acid is defined either by its method of production or its structure. In reference to its method of production, e.g., a product made by a process, the process is use of recombinant nucleic acid techniques, e.g., involving human intervention in the nucleotide sequence, typically selection or production. Alternatively, it can be a nucleic acid made by generating a sequence comprising fusion of two fragments which are not naturally contiguous to each other, but is meant to exclude products of nature, e.g., naturally occurring mutants. Thus, for example, products made by transforming cells with any unnaturally occurring vector is encompassed, as are nucleic acids comprising sequence derived using any synthetic oligonucleotide process. Such is often done to replace a codon with a redundant codon encoding the same or a conservative amino acid, while typically introducing or removing a sequence recognition site. Alternatively, it is performed to join together nucleic acid segments of desired functions to generate a single genetic entity comprising a desired combination of functions not found in the commonly available natural forms. Restriction enzyme recognition sites are often the target of such artificial manipulations, but other site specific targets, e.g., promoters, DNA replication sites, regulation sequences, control sequences, or other useful features may be incorporated by design. A similar concept is intended for a recombinant, e.g., fusion, polypeptide. Specifically included are synthetic nucleic acids which, by genetic code redundancy, encode polypeptides similar to fragments of these antigens, and fusions of sequences from various different species variants.

A significant "fragment" in a nucleic acid context is a contiguous segment of at least about 17 nucleotides, generally at least 20 nucleotides, more generally at least 23 nucleotides, ordinarily at least 26 nucleotides, more ordinarily at least 29 nucleotides, often at least 32 nucleotides, more often at least 35 nucleotides, typically at least 38 nucleotides, more typically at least 41 nucleotides, usually at least 44 nucleotides, more usually at least 47 nucleotides, preferably at least 50 nucleotides, more preferably at least 53 nucleotides, and in particularly preferred embodiments will be at least 56 or more nucleotides. Said fragments may have termini at any location, but especially at boundaries between structural domains.

A DNA which codes for a CRTAM protein will be particularly useful to identify genes, mRNA, and cDNA species which code for related or homologous proteins, as well as DNAs which code for homologous proteins. There are likely homologues in other primates. Various CRTAM proteins should be homologous and are encompassed herein. However, even proteins that have a more distant evolution-

ary relationship to the antigen can readily be isolated under appropriate conditions using these sequences if they are sufficiently homologous. Primate CRTAM proteins are of particular interest.

This invention further covers recombinant DNA molecules and fragments having a DNA sequence identical to or highly homologous to the isolated DNAs set forth herein. In particular, the sequences will often be operably linked to DNA segments which control transcription, translation, and DNA replication. Alternatively, recombinant clones derived from the genomic sequences, e.g., containing introns, will be useful for transgenic studies, including, e.g., transgenic cells and organisms, and for gene therapy. See, e.g., Goodnow (1992) "Transgenic Animals" in Roitt (ed.) *Encyclopedia of Immunology* Academic Press, San Diego, pp. 1502-1504; Travis (1992) *Science* 256:1392-1394; Kuhn et al. (1991) *Science* 254:707-710; Capecchi (1989) *Science* 244:1288; Robertson (1987) (ed.) *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach* IRL Press, Oxford; and Rosenberg (1992) *J. Clinical Oncology* 10:180-199; each of which is incorporated herein by reference.

Homologous nucleic acid sequences, when compared, exhibit significant similarity. The standards for homology in nucleic acids are either measures for homology generally used in the art by sequence comparison or based upon hybridization conditions. The hybridization conditions are described in greater detail below.

Substantial homology in the nucleic acid sequence comparison context means either that the segments, or their complementary strands, when compared, are identical when optimally aligned, with appropriate nucleotide insertions or deletions, in at least about 50% of the nucleotides, generally at least 56%, more generally at least 59%, ordinarily at least 62%, more ordinarily at least 65%, often at least 68%, more often at least 71%, typically at least 74%, more typically at least 77%, usually at least 80%, more usually at least about 85%, preferably at least about 90%, more preferably at least about 95 to 98% or more, and in particular embodiments, as high as about 99% or more of the nucleotides. Alternatively, substantial homology exists when the segments will hybridize under selective hybridization conditions, to a strand, or its complement, typically using a sequence derived from Table 3 or 4. Typically, selective hybridization will occur when there is at least about 55% homology over a stretch of at least about 14 nucleotides, preferably at least about 65%, more preferably at least about 75%, and most preferably at least about 90%. See, Kanehisa (1984) *Nuc. Acids Res.* 12:203-213, which is incorporated herein by reference. The length of homology comparison, as described, may be over longer stretches, and in certain embodiments will be over a stretch of at least about 17 nucleotides, usually at least about 20 nucleotides, more usually at least about 24 nucleotides, typically at least about 28 nucleotides, more typically at least about 40 nucleotides, preferably at least about 50 nucleotides, and more preferably at least about 75 to 100 or more nucleotides.

Stringent conditions, in referring to homology in the hybridization context, will be stringent combined conditions of salt, temperature, organic solvents, and other parameters, typically those controlled in hybridization reactions. Stringent temperature conditions will usually include temperatures in excess of about 30° C., more usually in excess of about 37° C., typically in excess of about 45° C., more typically in excess of about 55° C., preferably in excess of about 65° C., and more preferably in excess of about 70° C. Stringent salt conditions will ordinarily be less than about 1000 mM, usually less than about 500 mM, more usually

less than about 400 mM, typically less than about 300 mM, preferably less than about 200 mM, and more preferably less than about 150 mM. However, the combination of parameters is much more important than the measure of any single parameter. See, e.g., Wetmur and Davidson (1968) *J. Mol. Biol.* 31:349-370, which is hereby incorporated herein by reference.

### III. Purified CRTAM protein

The predicted sequence of human CRTAM amino acid sequence is shown in Table 3. The peptide sequences allow preparation of peptides to generate antibodies to recognize such segments. As used herein, CRTAM shall encompass, when used in a protein context, a protein having amino acid sequences shown in Table 3 or 4, or a significant fragment of such a protein. It also refers to a primate, e.g., human, derived polypeptide which exhibits similar biological function or interacts with CRTAM protein specific binding components. These binding components, e.g., antibodies, typically bind to a CRTAM protein with high affinity, e.g., at least about 100 nM, usually better than about 30 nM, preferably better than about 10 nM, and more preferably at better than about 3 nM.

The term polypeptide, as used herein, includes a significant fragment or segment, and encompasses a stretch of amino acid residues of at least about 8 amino acids, generally at least 10 amino acids, more generally at least 12 amino acids, often at least 14 amino acids, more often at least 16 amino acids, typically at least 18 amino acids, more typically at least 20 amino acids, usually at least 22 amino acids, more usually at least 24 amino acids, preferably at least 26 amino acids, more preferably at least 28 amino acids, and, in particularly preferred embodiments, at least about 30 or more amino acids. The specific ends of such a segment will be at any combinations within the protein. Preferably the fragment will encompass structural domains, e.g., 3-286, 39-97, 142-195, 287-310, or 311-393.

Substantially pure, in the polypeptide context, typically means that the protein is free from other contaminating proteins, nucleic acids, and other biologicals derived from the original source organism. Purity may be assayed by standard methods, and will ordinarily be at least about 40% pure, more ordinarily at least about 50% pure, generally at least about 60% pure, more generally at least about 70% pure, often at least about 75% pure, more often at least about 80% pure, typically at least about 85% pure, more typically at least about 90% pure, preferably at least about 95% pure, more preferably at least about 98% pure, and in most preferred embodiments, at least 99% pure. The analysis may be weight or molar percentages, evaluated, e.g., by gel staining, spectrophotometry, or terminus labeling.

A binding composition refers to molecules that bind with specificity to CRTAM protein, e.g., in a ligand-receptor type fashion, an antibody-antigen interaction, or compounds, e.g., proteins which specifically associate with CRTAM protein, e.g., in a natural physiologically relevant protein-protein interaction, either covalent or non-covalent. The molecule may be a polymer, or chemical reagent. No implication as to whether CRTAM protein is either the ligand or the receptor of a ligand-receptor interaction is represented, other than the interaction exhibit similar specificity, e.g., specific affinity. A functional analog may be a protein with structural modifications, or may be a wholly unrelated molecule, e.g., which has a molecular shape which interacts with the appropriate binding determinants. The proteins may serve as agonists or antagonists of a receptor, see, e.g., Goodman et al. (eds.) (1990) *Goodman & Gilman's: The Pharmacological Bases of Therapeutics* (8th ed.), Pergamon Press.

Solubility of a polypeptide or fragment depends upon the environment and the polypeptide. Many parameters affect polypeptide solubility, including temperature, electrolyte environment, size and molecular characteristics of the polypeptide, and nature of the solvent. Typically, the temperature at which the polypeptide is used ranges from about 4° C. to about 65° C. Usually the temperature at use is greater than about 18° C. and more usually greater than about 22° C. For diagnostic purposes, the temperature will usually be about room temperature or warmer, but less than the denaturation temperature of components in the assay. For therapeutic purposes, the temperature will usually be body temperature, typically about 37° C. for humans, though under certain situations the temperature may be raised or lowered in situ or in vitro.

The electrolytes will usually approximate in situ physiological conditions, but may be modified to higher or lower ionic strength where advantageous. The actual ions may be modified, e.g., to conform to standard buffers used in physiological or analytical contexts.

The size and structure of the polypeptide should generally be in a substantially stable state, and usually not in a denatured state. The polypeptide may be associated with other polypeptides in a quaternary structure, e.g., to confer solubility, or associated with lipids or detergents in a manner which approximates natural lipid bilayer interactions.

The solvent will usually be a biologically compatible buffer, of a type used for preservation of biological activities, and will usually approximate a physiological solvent. Usually the solvent will have a neutral pH, typically between about 5 and 10, and preferably about 7.5. On some occasions, a detergent will be added, typically a mild non-denaturing one, e.g., CHS or CHAPS, or a low enough concentration as to avoid significant disruption of structural or physiological properties of the antigen.

Solubility is reflected by sedimentation measured in Svedberg units, which are a measure of the sedimentation velocity of a molecule under particular conditions. The determination of the sedimentation velocity was classically performed in an analytical ultracentrifuge, but is typically now performed in a standard ultracentrifuge. See, Freifelder (1982) *Physical Biochemistry* (2d ed.), W. H. Freeman; and Cantor and Schimmel (1980) *Biophysical Chemistry*, parts 1-3, W. H. Freeman & Co., San Francisco; each of which is hereby incorporated herein by reference. As a crude determination, a sample containing a putatively soluble polypeptide is spun in a standard full sized ultracentrifuge at about 50K rpm for about 10 minutes, and soluble molecules will remain in the supernatant. A soluble particle or polypeptide will typically be less than about 30 S, more typically less than about 15 S, usually less than about 10 S, more usually less than about 6 S, and, in particular embodiments, preferably less than about 4 S, and more preferably less than about 3 S.

#### IV. Making CRTAM protein; Mimetics

DNA which encodes the CRTAM protein or fragments thereof can be obtained by chemical synthesis, screening cDNA libraries, or by screening genomic libraries prepared from a wide variety of cell lines or tissue samples.

This DNA can be expressed in a wide variety of host cells for the synthesis of a full-length protein or fragments which can in turn, for example, be used to generate polyclonal or monoclonal antibodies; for binding studies; for construction and expression of modified molecules; and for structure/function studies. Each antigen or its fragments can be expressed in host cells that are transformed or transfected with appropriate expression vectors. These molecules can be

substantially purified to be free of protein or cellular contaminants, other than those derived from the recombinant host, and therefore are particularly useful in pharmaceutical compositions when combined with a pharmaceutically acceptable carrier and/or diluent. The antigen, or portions thereof, may be expressed as fusions with other proteins.

Expression vectors are typically self-replicating DNA or RNA constructs containing the desired antigen gene or its fragments, usually operably linked to suitable genetic control elements that are recognized in a suitable host cell. These control elements are capable of effecting expression within a suitable host. The specific type of control elements necessary to effect expression will depend upon the eventual host cell used. Generally, the genetic control elements can include a prokaryotic promoter system or a eukaryotic promoter expression control system, and typically include a transcriptional promoter, an optional operator to control the onset of transcription, transcription enhancers to elevate the level of mRNA expression, a sequence that encodes a suitable ribosome binding site, and sequences that terminate transcription and translation. Expression vectors also usually contain an origin of replication that allows the vector to replicate independently of the host cell.

The vectors of this invention contain DNA which encodes a CRTAM protein, or a fragment thereof, typically encoding a biologically active polypeptide. The DNA can be under the control of a viral promoter and can encode a selection marker. This invention further contemplates use of such expression vectors which are capable of expressing eukaryotic cDNA coding for a CRTAM protein in a prokaryotic or eukaryotic host, where the vector is compatible with the host and where the eukaryotic cDNA coding for the antigen is inserted into the vector such that growth of the host containing the vector expresses the cDNA in question. Usually, expression vectors are designed for stable replication in their host cells or for amplification to greatly increase the total number of copies of the desirable gene per cell. It is not always necessary to require that an expression vector replicate in a host cell, e.g., it is possible to effect transient expression of the antigen or its fragments in various hosts using vectors that do not contain a replication origin that is recognized by the host cell. It is also possible to use vectors that cause integration of a CRTAM gene or its fragments into the host DNA by recombination, or to integrate a promoter which controls expression of an endogenous gene.

Vectors, as used herein, comprise plasmids, viruses, bacteriophage, integratable DNA fragments, and other vehicles which enable the integration of DNA fragments into the genome of the host. Expression vectors are specialized vectors which contain genetic control elements that effect expression of operably linked genes. Plasmids are the most commonly used form of vector but all other forms of vectors which serve an equivalent function and which are, or become, known in the art are suitable for use herein. See, e.g., Pouwels et al. (1985 and Supplements) *Cloning Vectors: A Laboratory Manual*, Elsevier, N.Y., and Rodriguez et al. (1988) (eds.) *Vectors: A Survey of Molecular Cloning Vectors and Their Uses*, Butterworth, Boston, Mass., which are incorporated herein by reference.

Transformed cells include cells, preferably mammalian, that have been transformed or transfected with vectors containing a CRTAM gene, typically constructed using recombinant DNA techniques. Transformed host cells usually express the antigen or its fragments, but for purposes of cloning, amplifying, and manipulating its DNA, do not need to express the protein. This invention further contemplates



culturing transformed cells in a nutrient medium, thus permitting the protein to accumulate in the culture. The protein can be recovered, either from the culture or from the culture medium.

For purposes of this invention, DNA sequences are operably linked when they are functionally related to each other. For example, DNA for a presequence or secretory leader is operably linked to a polypeptide if it is expressed as a preprotein or participates in directing the polypeptide to the cell membrane or in secretion of the polypeptide. A promoter is operably linked to a coding sequence if it controls the transcription of the polypeptide; a ribosome binding site is operably linked to a coding sequence if it is positioned to permit translation. Usually, operably linked means contiguous and in reading frame, however, certain genetic elements such as repressor genes are not contiguously linked but still bind to operator sequences that in turn control expression.

Suitable host cells include prokaryotes, lower eukaryotes, and higher eukaryotes. Prokaryotes include both gram negative and gram positive organisms, e.g., *E. coli* and *B. subtilis*. Lower eukaryotes include yeasts, e.g., *S. cerevisiae* and *Pichia*, and species of the genus *Dictyostelium*. Higher eukaryotes include established tissue culture cell lines from animal cells, both of non-mammalian origin, e.g., insect cells, and birds, and of mammalian origin, e.g., human, primates, and rodents.

Prokaryotic host-vector systems include a wide variety of vectors for many different species. As used herein, *E. coli* and its vectors will be used generically to include equivalent vectors used in other prokaryotes. A representative vector for amplifying DNA is pBR322 or many of its derivatives. Vectors that can be used to express the CRTAM proteins or its fragments include, but are not limited to, such vectors as those containing the lac promoter (pUC-series); trp promoter (pBR322-trp); Ipp promoter (the pIN-series); lambda-pP or pR promoters (pOTS); or hybrid promoters such as ptac (pDR540). See Brosius et al. (1988) "Expression Vectors Employing Lambda-, trp-, lac-, and Ipp-derived Promoters", in Rodriguez and Denhardt (eds.) *Vectors: A Survey of Molecular Cloning Vectors and Their Uses*, Butterworth, Boston, Chapter 10, pp. 205-236, which is incorporated herein by reference.

Lower eukaryotes, e.g., yeasts and *Dictyostelium*, may be transformed with vectors encoding CRTAM proteins. For purposes of this invention, the most common lower eukaryotic host is the baker's yeast, *Saccharomyces cerevisiae*. It will be used to generically represent lower eukaryotes although a number of other strains and species are also available. Yeast vectors typically consist of a replication origin (unless of the integrating type), a selection gene, a promoter, DNA encoding the desired protein or its fragments, and sequences for translation termination, polyadenylation, and transcription termination. Suitable expression vectors for yeast include such constitutive promoters as 3-phosphoglycerate kinase and various other glycolytic enzyme gene promoters or such inducible promoters as the alcohol dehydrogenase 2 promoter or metallothionein promoter. Suitable vectors include derivatives of the following types: self-replicating low copy number (such as the YRp-series), self-replicating high copy number (such as the YEpl-series); integrating types (such as the YIp-series), or mini-chromosomes (such as the YCp-series).

Higher eukaryotic tissue culture cells are the preferred host cells for expression of the functionally active CRTAM protein. In principle, any higher eukaryotic tissue culture cell line is workable, e.g., insect baculovirus expression systems, whether from an invertebrate or vertebrate source.

However, mammalian cells are preferred, in that the processing, both cotranslationally and posttranslationally. Transformation or transfection and propagation of such cells has become a routine procedure. Examples of useful cell lines include HeLa cells, Chinese hamster ovary (CHO) cell lines, baby rat kidney (BRK) cell lines, insect cell lines, bird cell lines, and monkey (COS) cell lines. Expression vectors for such cell lines usually include an origin of replication, a promoter, a translation initiation site, RNA splice sites (if genomic DNA is used), a polyadenylation site, and a transcription termination site. These vectors also usually contain a selection gene or amplification gene. Suitable expression vectors may be plasmids, viruses, or retroviruses carrying promoters derived, e.g., from such sources as from adenovirus, SV40, parvoviruses, vaccinia virus, or cytomegalovirus. Representative examples of suitable expression vectors include pCDNA1; pCD, see Okayama et al. (1985) *Mol. Cell Biol.* 5:1136-1142; pMC1neo Poly-A, see Thomas et al. (1987) *Cell* 51:503-512; and a baculovirus vector such as pAC 373 or pAC 610.

It will often be desired to express a CRTAM protein polypeptide in a system which provides a specific or defined glycosylation pattern. In this case, the usual pattern will be that provided naturally by the expression system. However, the pattern will be modifiable by exposing the polypeptide, e.g., an unglycosylated form, to appropriate glycosylating proteins introduced into a heterologous expression system. For example, the CRTAM protein gene may be co-transformed with one or more genes encoding mammalian or other glycosylating enzymes. Using this approach, certain mammalian glycosylation patterns will be achievable or approximated in prokaryote or other cells.

The CRTAM protein, or a fragment thereof, may be engineered to be phosphatidyl inositol (PI) linked to a cell membrane, but can be removed from membranes by treatment with a phosphatidyl inositol cleaving enzyme, e.g., phosphatidyl inositol phospholipase-C. This releases the antigen in a biologically active form, and allows purification by standard procedures of protein chemistry. See, e.g., Low (1989) *Biochim. Biophys. Acta* 988:427-454; Tse et al. (1985) *Science* 230:1003-1008; and Brunner et al. (1991) *J. Cell Biol.* 114:1275-1283.

Now that the CRTAM protein has been characterized, fragments or derivatives thereof can be prepared by conventional processes for synthesizing peptides. These include processes such as are described in Stewart and Young (1984) *Solid Phase Peptide Synthesis*, Pierce Chemical Co., Rockford, Ill.; Bodanszky and Bodanszky (1984) *The Practice of Peptide Synthesis*, Springer-Verlag, New York; and Bodanszky (1984) *The Principles of Peptide Synthesis*, Springer-Verlag, New York; all of each are incorporated herein by reference. For example, an azide process, an acid chloride process, an acid anhydride process, a mixed anhydride process, an active ester process (for example, p-nitrophenyl ester, N-hydroxysuccinimide ester, or cyanomethyl ester), a carbodiimidazole process, an oxidative-reductive process, or a dicyclohexylcarbodiimide (DCCD)/additive process can be used. Solid phase and solution phase syntheses are both applicable to the foregoing processes.

The CRTAM protein, fragments, or derivatives are suitably prepared in accordance with the above processes as typically employed in peptide synthesis, generally either by a so-called stepwise process which comprises condensing an amino acid to the terminal amino acid, one by one in sequence, or by coupling peptide fragments to the terminal amino acid. Amino groups that are not being used in the coupling reaction are typically protected to prevent coupling at an incorrect location.

If a solid phase synthesis is adopted, the C-terminal amino acid is bound to an insoluble carrier or support through its carboxyl group. The insoluble carrier is not particularly limited as long as it has a binding capability to a reactive carboxyl group. Examples of such insoluble carriers include halomethyl resins, such as chloromethyl resin or bromomethyl resin, hydroxymethyl resins, phenol resins, tert-alkyloxycarbonyl-hydrazidated resins, and the like.

An amino group-protected amino acid is bound in sequence through condensation of its activated carboxyl group and the reactive amino group of the previously formed peptide or chain, to synthesize the peptide step by step. After synthesizing the complete sequence, the peptide is split off from the insoluble carrier to produce the peptide. This solid-phase approach is generally described by Merrifield et al. (1963) in *J. Am. Chem. Soc.* 85:2149-2156, which is incorporated herein by reference.

The prepared protein and fragments thereof can be isolated and purified from the reaction mixture by means of peptide separation, for example, by extraction, precipitation, electrophoresis and various forms of chromatography, and the like. The CRTAM proteins of this invention can be obtained in varying degrees of purity depending upon its desired use. Purification can be accomplished by use of the protein purification techniques disclosed herein or by the use of the antibodies herein described in immunoabsorbant affinity chromatography. This immunoabsorbant affinity chromatography is carried out by first linking the antibodies to a solid support and then contacting the linked antibodies with solubilized lysates of appropriate source cells, lysates of other cells expressing the protein, or lysates or supernatants of cells producing the CRTAM protein as a result of DNA techniques, see below.

#### V. Physical Variants

This invention also encompasses proteins or peptides having substantial amino acid sequence homology with the amino acid sequence of the CRTAM protein. The variants include species and allelic variants.

Amino acid sequence homology, or sequence identity, is determined by optimizing residue matches, if necessary, by introducing gaps as required. This changes when considering conservative substitutions as matches. Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. Homologous amino acid sequences are typically intended to include natural allelic and interspecies variations in each respective protein sequence. Typical homologous proteins or peptides will have from 25-100% homology (if gaps can be introduced), to 50-100% homology (if conservative substitutions are included) with the amino acid sequence of the CRTAM protein. Homology measures will be at least about 35%, generally at least 40%, more generally at least 45%, often at least 50%, more often at least 55%, typically at least 60%, more typically at least 65%, usually at least 70%, more usually at least 75%, preferably at least 80%, and more preferably at least 85%, and in particularly preferred embodiments, at least 85% or more. See also Needleham et al. (1970) *J. Mol. Biol.* 48:443-453; Sankoff et al. (1983) Chapter One in *Time Warps, String Edits, and Macromolecules: The Theory and Practice of Sequence Comparison* Addison-Wesley, Reading, Mass.; and software packages from IntelliGenetics, Mountain View, Calif.; and the University of Wisconsin Genetics Computer Group, Madison, Wis.; each of which is incorporated herein by reference.

The isolated DNA encoding a CRTAM protein can be readily modified by nucleotide substitutions, nucleotide

deletions, nucleotide insertions, and inversions of nucleotide stretches. These modifications result in novel DNA sequences which encode these antigens, their derivatives, or proteins having similar physiological, immunogenic, or antigenic activity. These modified sequences can be used to produce mutant antigens or to enhance expression. Enhanced expression may involve gene amplification, increased transcription, increased translation, and other mechanisms. Such mutant CRTAM protein derivatives include predetermined or site-specific mutations of the respective protein or its fragments. "Mutant CRTAM protein" encompasses a polypeptide otherwise falling within the homology definition of the human CRTAM protein as set forth above, but having an amino acid sequence which differs from that of CRTAM protein as found in nature, whether by way of deletion, substitution, or insertion. In particular, "site specific mutant CRTAM protein" generally includes proteins having significant homology with a protein having sequences of Table 3, and as sharing various biological activities, e.g., antigenic or immunogenic, with those sequences, and in preferred embodiments contain most of the disclosed sequences. Similar concepts apply to different CRTAM proteins, particularly those found in various mammals, e.g., primates, including human. As stated before, it is emphasized that descriptions are generally meant to encompass all CRTAM proteins, not limited to the specific embodiment discussed.

Although site specific mutation sites are predetermined, mutants need not be site specific. CRTAM protein mutagenesis can be conducted by making amino acid insertions or deletions. Substitutions, deletions, insertions, or any combinations may be generated to arrive at a final construct. Insertions include amino- or carboxy-terminal fusions. Random mutagenesis can be conducted at a target codon and the expressed mutants can then be screened for the desired activity. Methods for making substitution mutations at predetermined sites in DNA having a known sequence are well known in the art, e.g., by M13 primer mutagenesis or polymerase chain reaction (PCR) techniques. See also Sambrook et al. (1989) and Ausubel et al. (1987 and Supplements).

The mutations in the DNA normally should not place coding sequences out of reading frames and preferably will not create complementary regions that could hybridize to produce secondary mRNA structure such as loops or hairpins.

The present invention also provides recombinant proteins, e.g., heterologous fusion proteins using segments from these proteins. A heterologous fusion protein is a fusion of proteins or segments which are naturally not normally fused in the same manner. Thus, the fusion product of an immunoglobulin with a CRTAM polypeptide is a continuous protein molecule having sequences fused in a typical peptide linkage, typically made as a single translation product and exhibiting properties derived from each source peptide. A similar concept applies to heterologous nucleic acid sequences.

In addition, new constructs may be made from combining similar functional domains from other proteins. For example, antigen-binding or other segments may be "swapped" between different new fusion polypeptides or fragments. See, e.g., Cunningham et al. (1989) *Science* 243:1330-1336; and O'Dowd et al. (1988) *J. Biol. Chem.* 263:15985-15992, each of which is incorporated herein by reference. Thus, new chimeric polypeptides exhibiting new combinations of specificities will result from the functional linkage of biologically relevant domains and other functional domains.

The phosphoramidite method described by Beaucage and Carruthers (1981) *Tetra. Letts.* 22:1859-1862, will produce suitable synthetic DNA fragments. A double stranded fragment will often be obtained either by synthesizing the complementary strand and annealing the strand together under appropriate conditions or by adding the complementary strand using DNA polymerase with an appropriate primer sequence, e.g., PCR techniques.

#### VI. Functional Variants

The blocking of physiological response to CRTAM proteins may result from the inhibition of binding of the antigen to its natural binding partner, e.g., through competitive inhibition. Thus, in vitro assays of the present invention will often use isolated protein, membranes from cells expressing a recombinant membrane associated CRTAM protein, soluble fragments comprising binding segments, or fragments attached to solid phase substrates. These assays will also allow for the diagnostic determination of the effects of either binding segment mutations and modifications, or protein mutations and modifications, e.g., analogues.

This invention also contemplates the use of competitive drug screening assays, e.g., where neutralizing antibodies to antigen or binding partner fragments compete with a test compound for binding to the protein. In this manner, the antibodies can be used to detect the presence of any polypeptide which shares one or more antigenic binding sites of the protein and can also be used to occupy binding sites on the protein that might otherwise interact with a binding partner.

Additionally, neutralizing antibodies against the CRTAM protein and soluble fragments of the antigen which contain a high affinity receptor binding site, can be used to inhibit antigen function in tissues, e.g., tissues experiencing abnormal physiology.

"Derivatives" of the CRTAM antigens include amino acid sequence mutants, glycosylation variants, and covalent or aggregate conjugates with other chemical moieties. Covalent derivatives can be prepared by linkage of functionalities to groups which are found in the CRTAM amino acid side chains or at the N- or C- termini, by means which are well known in the art. These derivatives can include, without limitation, aliphatic esters or amides of the carboxyl terminus, or of residues containing carboxyl side chains, O-acyl derivatives of hydroxyl group-containing residues, and N-acyl derivatives of the amino terminal amino acid or amino-group containing residues, e.g., lysine or arginine. Acyl groups are selected from the group of alkyl-moieties including C3 to C18 normal alkyl, thereby forming alkanoyl aroyl species. Covalent attachment to carrier proteins may be important when immunogenic moieties are haptens.

In particular, glycosylation alterations are included, e.g., made by modifying the glycosylation patterns of a polypeptide during its synthesis and processing, or in further processing steps. Particularly preferred means for accomplishing this are by exposing the polypeptide to glycosylating enzymes derived from cells which normally provide such processing, e.g., mammalian glycosylation enzymes. Deglycosylation enzymes are also contemplated. Also embraced are versions of the same primary amino acid sequence which have other minor modifications, including phosphorylated amino acid residues, e.g., phosphotyrosine, phosphoserine, or phosphothreonine.

A major group of derivatives are covalent conjugates of the CRTAM protein or fragments thereof with other proteins or polypeptides. These derivatives can be synthesized in recombinant culture such as N- or C-terminal fusions or by the use of agents known in the art for their usefulness in cross-linking proteins through reactive side groups. Pre-

ferred antigen derivatization sites with cross-linking agents are at free amino groups, carbohydrate moieties, and cysteine residues.

Fusion polypeptides between the CRTAM proteins and other homologous or heterologous proteins are also provided. Homologous polypeptides may be fusions between different surface markers, resulting in, e.g., a hybrid protein exhibiting receptor binding specificity. Likewise, heterologous fusions may be constructed which would exhibit a combination of properties or activities of the derivative proteins. Typical examples are fusions of a reporter polypeptide, e.g., luciferase, with a segment or domain of an antigen, e.g., a receptor-binding segment, so that the presence or location of the fused antigen may be easily determined. See, e.g., Dull et al., U.S. Pat. No. 4,859,609, which is hereby incorporated herein by reference. Other gene fusion partners include bacterial  $\beta$ -galactosidase, trpE, Protein A,  $\beta$ -lactamase, alpha amylase, alcohol dehydrogenase, and yeast alpha mating factor. See, e.g., Godowski et al. (1988) *Science* 241:812-816.

The phosphoramidite method described by Beaucage and Carruthers (1981) *Tetra, Letts*, 22:1859-1862, will produce suitable synthetic DNA fragments. A double stranded fragment will often be obtained either by synthesizing the complementary strand and annealing the strand together under appropriate conditions or by adding the complementary strand using DNA polymerase with an appropriate primer sequence.

Such polypeptides may also have amino acid residues which have been chemically modified by phosphorylation, sulfonation, biotinylation, or the addition or removal of other moieties, particularly those which have molecular shapes similar to phosphate groups. In some embodiments, the modifications will be useful labeling reagents, or serve as purification targets, e.g., affinity ligands.

Fusion proteins will typically be made by either recombinant nucleic acid methods or by synthetic polypeptide methods. Techniques for nucleic acid manipulation and expression are described generally, for example, in Sambrook et al. (1989) *Molecular Cloning: A Laboratory Manual* (2d ed.), Vols. 1-3, Cold Spring Harbor Laboratory, which are incorporated herein by reference. Techniques for synthesis of polypeptides are described, for example, in Merrifield (1963) *J. Amer. Chem. Soc.* 85:2149-2156; Merrifield (1986) *Science* 232: 341-347; and Atherton et al. (1989) *Solid Phase Peptide Synthesis: A Practical Approach*, IRL Press, Oxford; each of which is incorporated herein by reference.

This invention also contemplates the use of derivatives of the CRTAM proteins other than variations in amino acid sequence or glycosylation. Such derivatives may involve covalent or aggregative association with chemical moieties. These derivatives generally fall into the three classes: (1) salts, (2) side chain and terminal residue covalent modifications, and (3) adsorption complexes, for example with cell membranes. Such covalent or aggregative derivatives are useful as immunogens, as reagents in immunoassays, or in purification methods such as for affinity purification of antigens or other binding proteins. For example, a CRTAM antigen can be immobilized by covalent bonding to a solid support such as cyanogen bromide-activated Sepharose, by methods which are well known in the art, or adsorbed onto polyolefin surfaces, with or without glutaraldehyde cross-linking, for use in the assay or purification of anti-CRTAM protein antibodies or its receptor or other binding partner. The CRTAM antigens can also be labeled with a detectable group, for example radioiodinated

by the chloramine T procedure, covalently bound to rare earth chelates, or conjugated to another fluorescent moiety for use in diagnostic assays. Purification of CRTAM protein may be effected by immobilized antibodies or binding partners.

A solubilized CRTAM antigen or fragment of this invention can be used as an immunogen for the production of antisera or antibodies specific for the protein or fragments thereof. The purified antigen can be used to screen monoclonal antibodies or binding fragments prepared by immunization with various forms of impure preparations containing the protein. In particular, the term "antibodies" also encompasses antigen binding fragments of natural antibodies. The purified CRTAM proteins can also be used as a reagent to detect any antibodies generated in response to the presence of elevated levels of the protein or cell fragments containing the antigen, both of which may be diagnostic of an abnormal or specific physiological or disease condition. Additionally, antigen fragments may also serve as immunogens to produce the antibodies of the present invention, as described immediately below. For example, this invention contemplates antibodies raised against amino acid sequences encoded by nucleotide sequences shown in Table 3, or fragments of proteins containing them. In particular, this invention contemplates antibodies having binding affinity to or being raised against specific fragments which are predicted to lie outside of the lipid bilayer.

The invention also provides means to isolate a group of related antigens displaying both distinctness and similarities in structure, expression, and function. Elucidation of many of the physiological effects of the antigens will be greatly accelerated by the isolation and characterization of distinct species variants. In particular, the present invention provides useful probes for identifying additional homologous genetic entities in different species.

The isolated genes will allow transformation of cells lacking expression of a corresponding CRTAM protein, e.g., either species types or cells which lack corresponding antigens and should exhibit negative background activity. Expression of transformed genes will allow isolation of antigenically pure cell lines, with defined or single species variants. This approach will allow for more sensitive detection and discrimination of the physiological effects of CRTAM proteins. Subcellular fragments, e.g., cytoplasts or membrane fragments, can be isolated and used.

Dissection of the critical structural elements which effect the various physiological or differentiation functions provided by the proteins is possible using standard techniques of modern molecular biology, particularly in comparing members of the related class. See, e.g., the homolog-scanning mutagenesis technique described in Cunningham et al. (1989) *Science* 243:1339-1336; and approaches used in O'Dowd et al. (1988) *J. Biol. Chem.* 263:15985-15992; and Lechleiter et al. (1990) *EMBO J.* 9:4381-4390; each of which is incorporated herein by reference.

In particular, functional domains or segments can be substituted between species variants or related proteins to determine what structural features are important in both binding partner affinity and specificity, as well as signal transduction. An array of different variants will be used to screen for molecules exhibiting combined properties of interaction with different species variants of binding partners.

Antigen internalization may occur under certain circumstances, and interaction between intracellular components and "extracellular" segments of proteins involved in interactions may occur. The specific segments of interaction

of CRTAM protein with other intracellular components may be identified by mutagenesis or direct biochemical means, e.g., cross-linking or affinity methods. Structural analysis by crystallographic or other physical methods will also be applicable. Further investigation of the mechanism of biological function will include study of associated components which may be isolatable by affinity methods or by genetic means, e.g., complementation analysis of mutants.

Further study of the expression and control of CRTAM protein will be pursued. The controlling elements associated with the antigens may exhibit differential developmental, tissue specific, or other expression patterns. Upstream or downstream genetic regions, e.g., control elements, are of interest.

Structural studies of the antigen will lead to design of new variants, particularly analogues exhibiting agonist or antagonist properties on binding partners. This can be combined with previously described screening methods to isolate variants exhibiting desired spectra of activities.

Expression in other cell types will often result in glycosylation differences in a particular antigen. Various species variants may exhibit distinct functions based upon structural differences other than amino acid sequence. Differential modifications may be responsible for differential function, and elucidation of the effects are now made possible.

Thus, the present invention provides important reagents related to antigen-binding partner interaction. Although the foregoing description has focused primarily upon the human CRTAM protein, those of skill in the art will immediately recognize that the invention encompasses other closely related antigens, e.g., other primate species or allelic variants, as well as variants and other members of the family.

#### VII. Antibodies

Antibodies can be raised to the various CRTAM proteins, including species or allelic variants, and fragments thereof, both in their naturally occurring forms and in their recombinant forms. Additionally, antibodies can be raised to CRTAM proteins in either their active forms or in their inactive forms. Anti-idiotypic antibodies are also contemplated.

Antibodies, including binding fragments and single chain versions, against predetermined fragments of the antigens can be raised by immunization of animals with conjugates of the fragments with immunogenic proteins. Monoclonal antibodies are prepared from cells secreting the desired antibody. These antibodies can be screened for binding to normal or defective CRTAM proteins, or screened for agonistic or antagonistic activity, e.g., mediated through a binding partner. These monoclonal antibodies will usually bind with at least a  $K_D$  of about 1 mM, more usually at least about 300  $\mu$ M, typically at least about 100  $\mu$ M, more typically at least about 30 preferably at least about 10  $\mu$ M, and more preferably at least about 3  $\mu$ M or better.

The antibodies, including antigen binding fragments, of this invention can have significant diagnostic or therapeutic value. They can be potent antagonists that bind to a binding partner and inhibit antigen binding or inhibit the ability of an antigen to elicit a biological response. They also can be useful as non-neutralizing antibodies and can be coupled to toxins or radionuclides so that when the antibody binds to the antigen, a cell expressing it, e.g., on its surface, is killed. Further, these antibodies can be conjugated to drugs or other therapeutic agents, either directly or indirectly by means of a linker, and may effect drug targeting.

The antibodies of this invention can also be useful in diagnostic applications. As capture or non-neutralizing antibodies, they can be screened for ability to bind to the

antigens without inhibiting binding by a partner. As neutralizing antibodies, they can be useful in competitive binding assays. They will also be useful in detecting or quantifying CRTAM protein or its binding partners. Antigen fragments may be joined to other materials, particularly polypeptides, as fused or covalently joined polypeptides to be used as immunogens. An antigen and its fragments may be fused or covalently linked to a variety of immunogens, such as keyhole limpet hemocyanin, bovine serum albumin, tetanus toxoid, etc. See *Microbiology*, Hoeber Medical Division, Harper and Row, 1969; Landsteiner (1962) *Specificity of Serological Reactions*, Dover Publications, New York, and Williams et al. (1967) *Methods in Immunology and Immunochemistry*, Vol. 1, Academic Press, New York, each of which are incorporated herein by reference, for descriptions of methods of preparing polyclonal antisera. A typical method involves hyperimmunization of an animal with an antigen. The blood of the animal is then collected shortly after the repeated immunizations and the gamma globulin is isolated.

In some instances, it is desirable to prepare monoclonal antibodies from various mammalian hosts, such as mice, rodents, primates, humans, etc. Description of techniques for preparing such monoclonal antibodies may be found in, e.g., Stites et al. (eds.) *Basic and Clinical Immunology* (4th ed.), Lange Medical Publications, Los Altos, Calif., and references cited therein; Harlow and Lane (1988) *Antibodies: A Laboratory Manual*, CSH Press; Goding (1986) *Monoclonal Antibodies: Principles and Practice* (2d ed.) Academic Press, New York; and particularly in Kohler and Milstein (1975) in *Nature* 256: 495-497, which discusses one method of generating monoclonal antibodies. Each of these references is incorporated herein by reference. Summarized briefly, this method involves injecting an animal with an immunogen. The animal is then sacrificed and cells taken from its spleen, which are then fused with myeloma cells. The result is a hybrid cell or "hybridoma" that is capable of reproducing in vitro. The population of hybridomas is then screened to isolate individual clones, each of which secrete a single antibody species to the immunogen. In this manner, the individual antibody species obtained are the products of immortalized and cloned single B cells from the immune animal generated in response to a specific site recognized on the immunogenic substance.

Other suitable techniques involve in vitro exposure of lymphocytes to the antigenic polypeptides or alternatively to selection of libraries of antibodies in phage or similar vectors. See, Huse et al. (1989) "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," *Science* 246:1275-1281; and Ward et al. (1989) *Nature* 341:544-546, each of which is hereby incorporated herein by reference. The polypeptides and antibodies of the present invention may be used with or without modification, including chimeric or humanized antibodies. Frequently, the polypeptides and antibodies will be labeled by joining, either covalently or non-covalently, a substance which provides for a detectable signal. A wide variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, chemiluminescent moieties, magnetic particles, and the like. Patents, teaching the use of such labels include U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241. Also, recombinant immunoglobulins may be produced, see Cabilly, U.S. Pat. No. 4,816,567. These patents are incorporated herein by reference.

The antibodies of this invention can also be used for affinity chromatography in isolating the protein. Columns can be prepared where the antibodies are linked to a solid support, e.g., particles, such as agarose, Sephadex, or the like, where a cell lysate may be passed through the column, the column washed, followed by increasing concentrations of a mild denaturant, whereby the purified CRTAM protein will be released.

The antibodies may also be used to screen expression libraries for particular expression products. Usually the antibodies used in such a procedure will be labeled with a moiety allowing easy detection of presence of antigen by antibody binding. Antibodies raised against each CRTAM protein will also be useful to raise anti-idiotypic antibodies. These will be useful in detecting or diagnosing various immunological conditions related to expression of the respective antigens.

#### VIII. Uses

The present invention provides reagents which will find use in diagnostic applications as described elsewhere herein, e.g., in the general description for physiological or developmental abnormalities, or below in the description of kits for diagnosis.

This invention also provides reagents with significant therapeutic value. The CRTAM protein (naturally occurring or recombinant), fragments thereof, and antibodies thereto, along with compounds identified as having binding affinity to CRTAM protein, should be useful in the treatment of conditions associated with abnormal physiology or development, including abnormal proliferation, e.g., cancerous conditions, or degenerative conditions. Abnormal proliferation, regeneration, degeneration, and atrophy may be modulated by appropriate therapeutic treatment using the compositions provided herein. For example, a disease or disorder associated with abnormal expression or abnormal signaling by a CRTAM antigen should be a likely target for an agonist or antagonist of the protein.

Other abnormal developmental conditions are known in the cell types shown to possess CRTAM antigen mRNA by Northern blot analysis. See Berkow (ed.) *The Merck Manual of Diagnosis and Therapy*, Merck & Co., Rahway, N. J.; and Thorn et al. *Harrison's Principles of Internal Medicine*, McGraw-Hill, N.Y. These problems may be susceptible to prevention or treatment using compositions provided herein.

Recombinant antibodies which bind to CRTAM can be purified and then administered to a patient. These reagents can be combined for therapeutic use with additional active or inert ingredients, e.g., in conventional pharmaceutically acceptable carriers or diluents, e.g., immunogenic adjuvants, along with physiologically innocuous stabilizers and excipients. These combinations can be sterile filtered and placed into dosage forms as by lyophilization in dosage vials or storage in stabilized aqueous preparations. This invention also contemplates use of antibodies or binding fragments thereof, including forms which are not complement binding.

Screening using CRTAM for binding partners or compounds having binding affinity to CRTAM antigen can be performed, including isolation of associated components. Subsequent biological assays can then be utilized to determine if the compound has intrinsic biological activity and is therefore an agonist or antagonist in that it blocks an activity of the antigen. This invention further contemplates the therapeutic use of antibodies to CRTAM protein as antagonists. This approach should be particularly useful with other CRTAM protein species variants and other members of the family.

The quantities of reagents necessary for effective therapy will depend upon many different factors, including means of

administration, target site, physiological state of the patient, and other medicants administered. Thus, treatment dosages should be titrated to optimize safety and efficacy. Typically, dosages used in vitro may provide useful guidance in the amounts useful for in situ administration of these reagents. Animal testing of effective doses for treatment of particular disorders will provide further predictive indication of human dosage. Various considerations are described, e.g., in Gilman et al. (eds.) (1990) *Goodman and Gilman's: The Pharmacological Bases of Therapeutics*, 8th Ed., Pergamon Press; and Remington's *Pharmaceutical Sciences*, 17th ed. (1990), Mack Publishing Co., Easton, Pa.; each of which is hereby incorporated herein by reference. Methods for administration are discussed therein and below, e.g., for oral, intravenous, intraperitoneal, or intramuscular administration, transdermal diffusion, and others. Pharmaceutically acceptable carriers will include water, saline, buffers, and other compounds described, e.g., in the *Merck Index*, Merck & Co., Rahway, N.J. Dosage ranges would ordinarily be expected to be in amounts lower than 1 mM concentrations, typically less than about 10  $\mu$ M concentrations, usually less than about 100 nM, preferably less than about 10 pM (picomolar), and most preferably less than about 1 fM (femtomolar), with an appropriate carrier. Slow release formulations, or a slow release apparatus will often be utilized for continuous administration.

CRTAM protein, fragments thereof, and antibodies to it or its fragments, antagonists, and agonists, may be administered directly to the host to be treated or, depending on the size of the compounds, it may be desirable to conjugate them to carrier proteins such as ovalbumin or serum albumin prior to their administration. Therapeutic formulations may be administered in any conventional dosage formulation. While it is possible for the active ingredient to be administered alone, it is preferable to present it as a pharmaceutical formulation. Formulations typically comprise at least one active ingredient, as defined above, together with one or more acceptable carriers thereof. Each carrier should be both pharmaceutically and physiologically acceptable in the sense of being compatible with the other ingredients and not injurious to the patient. Formulations include those suitable for oral, rectal, nasal, or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. See, e.g., Gilman et al. (eds.) (1990) *Goodman and Gilman's: The Pharmacological Bases of Therapeutics*, 8th Ed., Pergamon Press; and Remington's *Pharmaceutical Sciences*, 17th ed. (1990), Mack Publishing Co., Easton, Pa.; each of which is hereby incorporated herein by reference. The therapy of this invention may be combined with or used in association with other chemotherapeutic or chemopreventive agents.

Both the naturally occurring and the recombinant form of the CRTAM proteins of this invention are particularly useful in kits and assay methods which are capable of screening compounds for binding activity to the proteins. Several methods of automating assays have been developed in recent years so as to permit screening of tens of thousands of compounds in a short period. See, e.g., Fodor et al. (1991) *Science* 251:767-773, which is incorporated herein by reference and which describes means for testing of binding affinity by a plurality of defined polymers synthesized on a solid substrate. The development of suitable assays can be greatly facilitated by the availability of large amounts of purified, soluble CRTAM protein as provided by this invention.

This invention is particularly useful for screening compounds by using recombinant antigen in any of a variety of drug screening techniques. The advantages of using a recombinant protein in screening for specific ligands include: (a) improved renewable source of the antigen from a specific source; (b) potentially greater number of antigen molecules per cell giving better signal to noise ratio in assays; and (c) species variant specificity (theoretically giving greater biological and disease specificity). The purified protein may be tested in numerous assays, typically in vitro assays, which evaluate biologically relevant responses. See, e.g., Coligan *Current Protocols in Immunology*; Hood et al. *Immunology Benjamin/Cummings*; Paul (ed.) *Fundamental Immunology*; and *Methods in Enzymology* Academic Press. This will also be useful in screening for a ligand which binds a CRTAM, e.g., from an interacting cell.

One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant DNA molecules expressing the CRTAM antigens. Cells may be isolated which express an antigen in isolation from other functionally equivalent antigens. Such cells, either in viable or fixed form, can be used for standard protein-protein binding assays. See also, Parce et al. (1989) *Science* 246:243-247; and Owicki et al. (1990) *Proc. Nat'l Acad. Sci. USA* 87:4007-4011, which are incorporated herein by reference and describe sensitive methods to detect cellular responses. Competitive assays are particularly useful, where the cells (source of CRTAM protein) are contacted and incubated with a labeled binding partner or antibody having known binding affinity to the ligand, such as  $^{125}$ I-antibody, and a test sample whose binding affinity to the binding composition is being measured. The bound and free labeled binding compositions are then separated to assess the degree of antigen binding. The amount of test compound bound is inversely proportional to the amount of labeled receptor binding to the known source. Any one of numerous techniques can be used to separate bound from free antigen to assess the degree of binding. This separation step could typically involve a procedure such as adhesion to filters followed by washing, adhesion to plastic followed by washing, or centrifugation of the cell membranes. Viable cells could also be used to screen for the effects of drugs on CRTAM protein mediated functions, e.g., second messenger levels, i.e.,  $Ca^{++}$ ; cell proliferation; inositol phosphate pool changes; and others. Some detection methods allow for elimination of a separation step, e.g., a proximity sensitive detection system. Calcium sensitive dyes will be useful for detecting  $Ca^{++}$  levels, with a fluorimeter or a fluorescence cell sorting apparatus.

Another method utilizes membranes from transformed eukaryotic or prokaryotic host cells as the source of the CRTAM protein. These cells are stably transformed with DNA vectors directing the expression of a membrane associated CRTAM protein, e.g., an engineered membrane bound form. Essentially, the membranes would be prepared from the cells and used in any receptor/ligand type binding assay such as the competitive assay set forth above.

Still another approach is to use solubilized, unpurified or solubilized, purified CRTAM protein from transformed eukaryotic or prokaryotic host cells. This allows for a "molecular" binding assay with the advantages of increased specificity, the ability to automate, and high drug test throughput.

Another technique for drug screening involves an approach which provides high throughput screening for compounds having suitable binding affinity to CRTAM and is described in detail in Geysen, European Patent Applica-

tion 84/03564, published on Sep. 13, 1984, which is incorporated herein by reference. First, large numbers of different small peptide test compounds are synthesized on a solid substrate, e.g., plastic pins or some other appropriate surface, see Fodor et al. (1991). Then all the pins are reacted with solubilized, unpurified or solubilized, purified CRTAM binding composition, and washed. The next step involves detecting bound binding composition.

Rational drug design may also be based upon structural studies of the molecular shapes of the CRTAM protein and other effectors or analogues. Effectors may be other proteins which mediate other functions in response to antigen binding, or other proteins which normally interact with the antigen, e.g., CRTAM ligand. One means for determining which sites interact with specific other proteins is a physical structure determination, e.g., x-ray crystallography or 2 dimensional NMR techniques. These will provide guidance as to which amino acid residues form molecular contact regions. For a detailed description of protein structural determination, see, e.g., Blundell and Johnson (1976) *Protein Crystallography*, Academic Press, New York, which is hereby incorporated herein by reference.

Purified CRTAM protein can be coated directly onto plates for use in the aforementioned drug screening techniques. However, non-neutralizing antibodies to these ligands can be used as capture antibodies to immobilize the respective ligand on the solid phase.

#### IX. Kits

This invention also contemplates use of CRTAM proteins, fragments thereof, peptides, and their fusion products in a variety of diagnostic kits and methods for detecting the presence of a binding composition. Typically the kit will have a compartment containing either a defined CRTAM peptide or gene segment or a reagent which recognizes one or the other, e.g., antigen fragments or antibodies.

A kit for determining the binding affinity of a test compound to a CRTAM protein would typically comprise a test compound; a labeled compound, for example an antibody having known binding affinity for the antigen; a source of CRTAM protein (naturally occurring or recombinant); and a means for separating bound from free labeled compound, such as a solid phase for immobilizing the antigen. Once compounds are screened, those having suitable binding affinity to the antigen can be evaluated in suitable biological assays, as are well known in the art, to determine whether they exhibit similar biological activities to the natural antigen. The availability of recombinant CRTAM protein polypeptides also provide well defined standards for calibrating such assays.

A preferred kit for determining the concentration of, for example, a CRTAM protein in a sample would typically comprise a labeled compound, e.g., antibody, having known binding affinity for the antigen, a source of antigen (naturally occurring or recombinant) and a means for separating the bound from free labeled compound, for example, a solid phase for immobilizing the CRTAM protein. Compartments containing reagents, and instructions, will normally be provided.

One method for determining the concentration of CRTAM protein in a sample would typically comprise the steps of: (1) preparing membranes from a sample comprised of a membrane bound CRTAM protein source; (2) washing the membranes and suspending them in a buffer; (3) solubilizing the antigen by incubating the membranes in a culture medium to which a suitable detergent has been added; (4) adjusting the detergent concentration of the solubilized antigen; (5) contacting and incubating said dilution with

radiolabeled antibody to form complexes; (6) recovering the complexes such as by filtration through polyethyleneimine treated filters; and (7) measuring the radioactivity of the recovered complexes.

Antibodies, including antigen binding fragments, specific for the CRTAM protein or fragments are useful in diagnostic applications to detect the presence of elevated levels of CRTAM protein and/or its fragments. Such diagnostic assays can employ lysates, live cells, fixed cells, immunofluorescence, cell cultures, body fluids, and further can involve the detection of antigens related to the protein in serum, or the like. Diagnostic assays may be homogeneous (without a separation step between free reagent and protein-protein complex) or heterogeneous (with a separation step). Various commercial assays exist, such as radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), enzyme immunoassay (EIA), enzyme-multiplied immunoassay technique (EMIT), substrate-labeled fluorescent immunoassay (SLFIA), and the like. For example, unlabeled antibodies can be employed by using a second antibody which is labeled and which recognizes the antibody to a CRTAM protein or to a particular fragment thereof. Similar assays have also been extensively discussed in the literature. See, e.g., Harlow and Lane (1988) *Antibodies: A Laboratory Manual*, CSH.

Anti-idiotypic antibodies may have similar use to diagnose presence of antibodies against a CRTAM protein, as such may be diagnostic of various abnormal states. For example, overproduction of CRTAM protein may result in production of various immunological reactions which may be diagnostic of abnormal physiological states, particularly in proliferative cell conditions such as cancer or abnormal differentiation.

Frequently, the reagents for diagnostic assays are supplied in kits, so as to optimize the sensitivity of the assays. For the subject invention, depending upon the nature of the assay, the protocol, and the label, either labeled or unlabeled antibody, or labeled CRTAM protein is provided. This is usually in conjunction with other additives, such as buffers, stabilizers, materials necessary for signal production such as substrates for enzymes, and the like. Preferably, the kit will also contain instructions for proper use and disposal of the contents after use. Typically the kit has compartments for each useful reagent. Desirably, the reagents are provided as a dry lyophilized powder, where the reagents may be reconstituted in an aqueous medium providing appropriate concentrations of reagents for performing the assay.

Any of the aforementioned constituents of the drug screening and the diagnostic assays may be used without modification or may be modified in a variety of ways. For example, labeling may be achieved by covalently or non-covalently joining a moiety which directly or indirectly provides a detectable signal. In any of these assays, the antigen, test compound, CRTAM protein, or antibodies thereto can be labeled either directly or indirectly. Possibilities for direct labeling include label groups: radiolabels such as  $^{125}\text{I}$ , enzymes (U.S. Pat. No. 3,645,090) such as peroxidase and alkaline phosphatase, and fluorescent labels (U.S. Pat. No. 3,940,475) capable of monitoring the change in fluorescence intensity, wavelength shift, or fluorescence polarization. Both of the patents are incorporated herein by reference. Possibilities for indirect labeling include biotinylation of one constituent followed by binding to avidin coupled to one of the above label groups.

There are also numerous methods of separating the bound from the free antigen, or alternatively the bound from the free test compound. The CRTAM protein can be immobi-

lized on various matrixes followed by washing. Suitable matrixes include plastic such as an ELISA plate, filters, and beads. Methods of immobilizing the CRTAM protein to a matrix include, without limitation, direct adhesion to plastic, use of a capture antibody, chemical coupling, and biotin-avidin. The last step in this approach involves the precipitation of protein-protein complex by any of several methods including those utilizing, e.g., an organic solvent such as polyethylene glycol or a salt such as ammonium sulfate. Other suitable separation techniques include, without limitation, the fluorescein antibody magnetizable particle method described in Rattle et al. (1984) *Clin. Chem.* 30:1457-1461, and the double antibody magnetic particle separation as described in U.S. Pat. No. 4,659,678, each of which is incorporated herein by reference.

The methods for linking proteins or their fragments to the various labels have been extensively reported in the literature and do not require detailed discussion here. Many of the techniques involve the use of activated carboxyl groups either through the use of carbodiimide or active esters to form peptide bonds, the formation of thioethers by reaction of a mercapto group with an activated halogen such as chloroacetyl, or an activated olefin such as maleimide, for linkage, or the like. Fusion proteins will also find use in these applications.

Another diagnostic aspect of this invention involves use of oligonucleotide or polynucleotide sequences taken from the sequence of a CRTAM protein. These sequences can be used as probes for detecting levels of antigen message in samples from patients suspected of having an abnormal condition, e.g., cancer or developmental problem. The preparation of both RNA and DNA nucleotide sequences, the labeling of the sequences, and the preferred size of the sequences has received ample description and discussion in the literature. Normally an oligonucleotide probe should have at least about 14 nucleotides, usually at least about 18 nucleotides, and the polynucleotide probes may be up to several kilobases. Various labels may be employed, most commonly radionuclides, particularly <sup>32</sup>P. However, other techniques may also be employed, such as using biotin modified nucleotides for introduction into a polynucleotide. The biotin then serves as the site for binding to avidin or antibodies, which may be labeled with a wide variety of labels, such as radionuclides, fluorescers, enzymes, or the like. Alternatively, antibodies may be employed which can recognize specific duplexes, including DNA duplexes, RNA duplexes, DNA-RNA hybrid duplexes, or DNA-protein duplexes. The antibodies in turn may be labeled and the assay carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected. The use of probes to the novel anti-sense RNA may be carried out in any conventional techniques such as nucleic acid hybridization, plus and minus screening, recombinational probing, hybrid released translation (HRT), and hybrid arrested translation (HART). This also includes amplification techniques such as polymerase chain reaction (PCR).

Diagnostic kits which also test for the qualitative or quantitative presence of other markers are also contemplated. Diagnosis or prognosis may depend on the combination of multiple indications used as markers. Thus, kits may test for combinations of markers. See, e.g., Viallet et al. (1989) *Progress in Growth Factor Res.* 1:89-97.

#### X. Methods for Isolating CRTAM Specific Binding Partners

The CRTAM protein should interact with a ligand based, e.g., upon its similarity in structure and function to other cell

markers exhibiting developmental and cell type specificity of expression. Methods to isolate a ligand are made available by the ability to make purified CRTAM for screening programs. Soluble or other constructs using the CRTAM sequences provided herein will allow for screening or isolation of CRTAM specific ligands.

The broad scope of this invention is best understood with reference to the following examples, which are not intended to limit the invention to specific embodiments.

## EXAMPLES

### I. General Methods

Some of the standard methods are described or referenced, e.g., in Maniatis et al. (1982) *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor Press; Sambrook et al. (1989) *Molecular Cloning: A Laboratory Manual*, (2d ed.), vols 1-3, CSH Press, NY; Ausubel et al., *Biology*, Greene Publishing Associates, Brooklyn, N.Y.; or Ausubel et al. (1987 and Supplements) *Current Protocols in Molecular Biology*, Greene/Wiley, New York; Innis et al. (eds.) (1990) *PCR Protocols; A Guide to Methods and Applications* Academic Press, N.Y.; all of which are each incorporated herein by reference. Methods for protein purification include such methods as ammonium sulfate precipitation, column chromatography, electrophoresis, centrifugation, crystallization, and others. See, e.g., Ausubel et al. (1987 and periodic supplements); Deutscher (1990) "Guide to Protein Purification" in *Methods in Enzymology*, vol. 182, and other volumes in this series; and manufacturer's literature on use of protein purification products, e.g., Pharmacia, Piscataway, N.J., or Bio-Rad, Richmond, Calif.; which are incorporated herein by reference. Combination with recombinant techniques allow fusion to appropriate segments, e.g., to a FLAG sequence or an equivalent which can be fused via a protease-removable sequence. See, e.g., Hochuli (1989) *Chemische Industrie* 12:69-70; Hochuli (1990) "Purification of Recombinant Proteins with Metal Chelate Absorbent" in Setlow (ed.) *Genetic Engineering, Principle and Methods* 12:87-98, Plenum Press, N.Y.; and Crowe et al. (1992) *OIAexpress: The High Level Expression & Protein Purification System* QUIAGEN, Inc., Chatsworth, Calif.; which are incorporated herein by reference.

FACS analyses are described in Melamed et al. (1990) *Flow Cytometry and Sorting* Wiley-Liss, Inc., New York, N.Y.; Shapiro (1988) *Practical Flow Cytometry* Liss, New York, N.Y.; and Robinson et al. (1993) *Handbook of Flow Cytometry Methods* Wiley-Liss, New York, N.Y.

### II. Preparation of antibodies specific for CRTAM.

Balb/c mice are immunized with cultured peripheral blood T cells. Splenocytes are fused with the Sp2/0 fusion partner and hybridomas are selected in growth medium containing azaserine by standard procedures.

In another method, synthetic peptides or purified protein are presented to an immune system to generate monoclonal or polyclonal antibodies. See, e.g., Coligan (1991) *Current Protocols in Immunology* Wiley/Greene; and Harlow and Lane (1989) *Antibodies: A Laboratory Manual* Cold Spring Harbor Press. In appropriate situations, the binding reagent is either labeled as described above, e.g., fluorescence or otherwise, or immobilized to a substrate for panning methods. Nucleic acids may also be introduced into cells in an animal to produce the antigen, which serves to elicit an immune response. See, e.g., Wang, et al. (1993) *Proc. Natl. Acad. Sci.* 90:4156-4160; Barry, et al. (1994) *BioTechniques* 16:616-619; and Xiang, et al. (1995) *Immunity* 2:129-135.



### III. Distribution of CRTAM Antigen.

CRTAM antigen distribution may be determined, e.g., by western blots, screening for message, FACS analysis, or other means. Total RNA from various cell lines, populations of cells, and tissues were isolated by standard methods. The RNA samples were then fractionated on denaturing agarose gels, transferred to a solid support, e.g., nitrocellulose, and hybridized with a CRTAM cDNA probe, as provided herein. Washed filters were subsequently exposed to X-ray film, or hybridization can be detected by other methods, e.g., histochemical type staining. CRTAM was found to be expressed on CD8+,  $\alpha\beta$ TCR+CD4-CD8-, and CD4+NK1.1+T cells. CRTAM expression was also found in mouse brain and testis tissue. CD4+ peripheral blood T cells expressed CRTAM, but at a lower level than CD8+ peripheral T cells. Screening may also be performed using immunohistochemical staining, using either indirect or direct labeling, as described above.

Further testing of populations of progenitor B cells or progenitor T cells should be screened. Other tissue types, at defined developmental stages, and pathology samples may be screened to determine what pathological states or stages may be advantageously correlated with the marker.

### IV Biochemical Characterization of the CRTAM protein.

A recombinant CRTAM construct is prepared, e.g., as a fusion product with a useful affinity reagent, e.g., FLAG peptide. This peptide segment may be useful for purifying the expression product of the construct. See, e.g., Crowe, et al. (1992) *OIAexpress: The High Level Expression & Protein Purification System* QUIAGEN, Inc. Chatsworth, Calif.; and Hopp, et al. (1988) *Bio/Technology* 6:1204-1210. The sequence allows for efficient affinity purification of the soluble product. Appropriate secretion or processing sites may also be engineered into the construct by standard methods. Purification is achieved, e.g., by use of affinity purification such as antibodies against the antigen, or by standard protein purification methods. Typically, the affinity reagents or purification procedures can be performed using recombinant receptor.

Affinity reagents can also be produced which allow isolation from natural sources. An ELISA may be developed to assist in developing a fractionation protocol, and the purified material should be subject to such characterization as molecular weight, glycosylation, post-translational modifications, amino acid analysis, behavior on various chromatographic analyses such as ion exchange, hydrophobic, size exclusion, HPLC, and others. The product should also be subject to various physical analyses, such as circular dichroism, NMR, mass spectroscopy, etc, before or after such processing as protease or other fragmentation.

### V. Purification of CRTAM protein

The CRTAM protein is isolated by a combination of affinity chromatography using the CRTAM specific binding compositions, e.g., antibody, as a specific binding reagent in combination with protein purification techniques allowing separation from other proteins and contaminants. Similar techniques using human cell assays and human cell sources are applied to isolate a native human antigen.

### VI. Isolation of a cDNA clone encoding CRTAM protein.

#### Antibodies and flow-cytometric sorting

Mouse  $\alpha\beta$ TcR+CD4-CD8- (DN) thymocytes were sorted using CD4/CD8a-PE and TcR $\alpha\beta$ -FITC mAbs (PharMingen, San Diego, Calif.). See Zlotnik, et al. (1992) *J. Immunol.* 4:1211-1215. The sorted cells (approximately  $5 \times 10^5$ ) were stimulated on solid-phase anti-CD3 for 24 h and were then expanded and cultured in IL-2 (500 U/ml) and IL-7 (100 U/ml) for one week (to approximately  $1 \times 10^8$

cells). Cells were either harvested after one week in culture or stimulated again for 6 h on anti-CD3 and then harvested.

#### Construction of directional cDNA libraries

Poly (A)+ RNA from anti-CD3 stimulated  $\alpha\beta$ DN thymocytes or unstimulated  $\alpha\beta$ DN thymocytes was used to synthesize first strand cDNA by using NotI/Oligo-dT primer (Gibco-BRL, Gaithersburg, Md.). Double-stranded cDNA was synthesized, ligated with BstXI systems, digested with NotI, size fractionated for >0.5 kilobase pairs (kb) and ligated into the NotI/BstXI sites of pJFE-14, a derivative of the pCDSR $\alpha$  vector. See Takebe, et al. *Mol Cell Biol.* 8:466-472. Electro-competent *E. coli* DH10 $\alpha$  cells (Gibco-BRL) were used for transformation. Total number of independent clones of the cDNA libraries were  $1.2 \times 10^6$  for stimulated  $\alpha\beta$ DN and  $8 \times 10^5$  for unstimulated  $\alpha\beta$ DN thymocytes, respectively.

#### Library subtraction

The PCR-based subtraction system developed by Wang and Brown (1991) *Proc. Natl. Acad. Sci. USA* 88:11505-11509, was modified to apply to plasmid cDNA libraries. A cDNA library specific for activated  $\alpha\beta$ DN thymocytes was generated using 100  $\mu$ g of the unstimulated  $\alpha\beta$ DN cDNA library DNA digested with XbaI, NotI, and ScaI as driver DNA and 5  $\mu$ g of the stimulated  $\alpha\beta$ DN cDNA library DNA as tracer DNA. Following restriction digestion, the driver DNA was treated with DNA polymerase Klenow fragment to fill-in the restriction sites. After ethanol precipitation, the DNA was dissolved in 100  $\mu$ l of water, heat-denatured and mixed with 100  $\mu$ l (100  $\mu$ g) of Photoprobe biotin (Vector Laboratories, Burlingame, Calif.). The driver DNA was then irradiated with a 270-W sunlamp on ice for 20 min. 50  $\mu$ l more Photoprobe biotin was added and the biotinylation reaction was repeated. After butanol extraction, the photobiotinylated DNA (driver-U) was ethanol-precipitated and dissolved in 30  $\mu$ l of 10 mM Tris-HCl and 1 mM EDTA, pH 8 (TE). As tracer DNA, 5  $\mu$ g of stimulated  $\alpha\beta$ DN cDNA was digested with XbaI and NotI; ethanol precipitated; and dissolved in 4  $\mu$ l of TE (tracer-S). Tracer-S was mixed with 15  $\mu$ l of driver-U, 1  $\mu$ l (10  $\mu$ g) of *E. coli* tRNA (Sigma, St. Louis, Mo.), and 20  $\mu$ l of 2 $\times$ hybridization buffer (1.5M NaCl, 10 mM EDTA, 50 mM HEPES, pH 7.5, 0.2% SDS), overlaid with mineral oil, and heat-denatured. The sample tube was immediately transferred into a 68 $^\circ$  C. water bath and incubated for 20 h. The reaction mixture was then subjected to streptavidin treatment followed by phenol/chloroform extraction. Subtracted DNA was precipitated, dissolved in 12  $\mu$ l of TE, mixed with 8  $\mu$ l of driver-U and 20  $\mu$ l of 2 $\times$ hybridization buffer, and then incubated at 68 $^\circ$  C. for 2 h. After streptavidin treatment, the remaining DNA was ligated with 250 ng of a purified XbaI/NotI fragment of pJFE-14 and then transformed into electro-competent *E. coli* cells to generate the activation specific  $\alpha\beta$ DN subtracted library (S1). 100 independent clones were randomly picked and screened by hybridization using a cocktail of known cytokine cDNA's. Plasmid DNA's were prepared from clones that did not hybridize to the cytokine probes. These clones were grouped by insert size and further characterized by DNA sequencing.

In another method, oligonucleotides are used to screen a library. In combination with polymerase chain reaction (PCR) techniques, synthetic oligonucleotides in appropriate orientations are used as primers to select correct clones from a library.

The CRTAM is used for screening of a library made from a cell line which expresses a CRTAM binding protein, e.g., a ligand. Standard staining techniques are used to detect or sort intracellular or surface expressed ligand, or surface



-continued

GGG Gly 55	TTC Phe	ACC Thr	ATT Ile	TTT Phe	TTA Leu 60	AAT Asn	GAG Glu	TAT Tyr	CCT Pro	GCT Ala 65	TTA Leu	AAA Lys	AAT Asn	TCC Ser	AAA Lys 70	247
TAC Tyr	CAG Gln	CTT Leu	CTT Leu	CAT His 75	CAC His	TCG Ser	GCC Ala	AAT Asn	CAG Gln 80	CTC Leu	TCC Ser	ATC Ile	ACT Thr	GTG Val 85	CCT Pro	295
AAC Asn	GTA Val	ACC Thr	CTG Leu 90	CAA Gln	GAT Asp	GAA Glu	GGC Gly	GTG Val 95	TAC Tyr	AAG Lys	TGC Cys	TTA Leu	CAT His 100	TAC Tyr	AGC Ser	343
GAC Asp	TCT Ser	GTA Val 105	AGC Ser	ACA Thr	AAG Lys	GAA Glu	GTG Val 110	AAA Lys	GTG Val 115	ATT Ile	GTG Val 115	CTG Leu	GCA Ala	ACT Thr	CCT Pro	391
TTC Phe 120	AAG Lys	CCA Pro	ATC Ile	CTG Leu	GAA Glu	GCT Ala 125	TCA Ser	GTT Val	ATC Ile	AGA Arg	AAG Lys 130	CAA Gln	AAT Asn	GGA Gly	GAA Glu	439
GAA Glu 135	CAT His	GTT Val	GTA Val	CTC Leu	ATG Met 140	TGC Cys	TCC Ser	ACC Thr	ATG Met 145	AGA Arg	AGC Ser	AAG Lys	CCC Pro	CCT Pro	CCG Pro 150	487
CAG Gln	ATA Ile	ACC Thr	TGG Trp	CTA Leu 155	CTT Leu	GGG Gly	AAT Asn	AGC Ser	ATG Met 160	GAA Glu	GTG Val	TCC Ser	GGT Gly	GGA Gly 165	ACG Thr	535
CTC Leu	CAT His	GAA Glu	TTT Phe 170	GAA Glu	ACT Thr	GAT Asp	GGG Gly	AAG Lys 175	AAA Lys	TGT Cys	AAT Asn	ACT Thr	ACC Thr 180	AGC Ser	ACT Thr	583
CTC Leu	ATA Ile	ATC Ile 185	CTC Leu	TCT Ser	TAT Tyr	GGC Gly	AAA Lys 190	AAT Asn	TCA Ser	ACG Thr	GTG Val	GAC Asp 195	TGC Cys	ATT Ile	ATC Ile	631
CGA Arg 200	CAC His	AGA Arg	GGC Gly	CTG Leu	CAA Gln	GGG Gly 205	AGA Arg	AAA Lys	CTA Leu	GTA Val	GCA Ala 210	CCC Pro	TTC Phe	CGG Arg	TTT Phe	679
GAA Glu 215	GAT Asp	TTG Leu	GTT Val	ACT Thr	GAT Asp 220	GAA Glu	GAG Glu	ACA Thr	GCT Ala	TCA Ser 225	GAT Asp	GCT Ala	CTG Leu	GAG Glu	AGA Arg 230	727
AAC Asn	TCT Ser	CTA Leu	TCC Ser	ACA Thr 235	CAA Gln	GAC Asp	CCA Pro	CAG Gln	CAG Gln 240	CCC Pro	ACC Thr	AGT Ser	ACT Thr	GTC Val 245	TCA Ser	775
GTA Val	ACG Thr	GAA Glu	GAT Asp 250	TCT Ser	AGT Ser	ACT Thr	TCG Ser	GAG Glu 255	ATT Ile	GAC Asp	AAG Lys	GAA Glu	GAG Glu 260	AAA Lys	GAA Glu	823
CAA Gln	ACC Thr	ACT Thr 265	CAA Gln	GAT Asp	CCT Pro	GAC Asp	TTG Leu 270	ACC Thr	ACC Thr	GAA Glu	GCA Ala	AAT Asn 275	CCT Pro	CAG Gln	TAT Tyr	871
TTA Leu 280	GGA Gly	CTG Leu	GCA Ala	AGA Arg	AAG Lys	AAA Lys 285	AGT Ser	GGC Gly	ATC Ile	CTG Leu	CTG Leu 290	CTC Leu	ACG Thr	CTG Leu	GTG Val	919
TCC Ser 295	TTC Phe	CTC Leu	ATT Ile	TTC Phe	ATA Ile 300	CTC Leu	TTC Phe	ATC Ile	ATA Ile	GTC Val 305	CAG Gln	CTC Leu	TTC Phe	ATC Ile	ATG Met 310	967
AAG Lys	CTG Leu	AGG Arg	AAA Lys	GCA Ala 315	CAT His	GTG Val	ATA Ile	TGG Trp	AAG Lys 320	AGA Arg	GAA Glu	AAC Asn	GAA Glu	GTT Val 325	TCA Ser	1015
GAA Glu	CAC His	ACA Thr	CTA Leu 330	GAA Glu	AGT Ser	TAC Tyr	AGA Arg	TCA Ser 335	AGG Arg	TCA Ser	AAT Asn	AAT Asn	GAA Glu 340	GAA Glu	ACA Thr	1063
TCA Ser	TCT Ser	GAA Glu 345	GAG Glu	AAA Lys	AAT Asn	GGC Gly	CAA Gln 350	TCT Ser	TCC Ser	CTC Leu	CCT Pro	ATG Met 355	CGT Arg	TGC Cys	ATG Met	1111
AAC Asn	TAC Tyr 360	ATC Ile	ACA Thr	AAG Lys	TTG Leu	TAC Tyr 365	TCA Ser	GAA Glu	GCA Ala	AAA Lys	ACA Thr 370	AAG Lys	AGG Arg	AAG Lys	GAA Glu	1159

-continued

AAT GTA CAA CAT TCA AAA TTA GAA GAA AAG CAC ATC CAA GTA CCA GAG	1207
Asn Val Gln His Ser Lys Leu Glu Glu Lys His Ile Gln Val Pro Glu	
375 380 385 390	
AGT ATT GTG TAGTGCTCTC TGCAATGGAA CATGTGATTT CAGGGTTGCC	1256
Ser Ile Val	
GCAGTGTAC CTCAGTGGAC CAGCCTGGGG GAAGGAGCTT AATTGCTGAG ACATTAATAA	1316
TGACCTCTTA GTGCAATGCA AGATGGTGTG CTCGGATAAT GATCTGCCCC GGAGCTAGGG	1376
CAGCAACATG AGGACCAAAC CATGCACATA AAGCTTGTAG TTTAAAAAAG AAAAGCAAAA	1436
AAATAATTAT GCCTGACACT ACTTCAGAGC AGGAGGATTC TACGAAGCCT TGGGGATCAG	1496
GGTCAGTGTG AGCAGCTAAC ATCCTACCTC AAATGGAACA GGATTTTTTG ATGCTTTGCT	1556
CTAATGGAAC TGTTTTAAAA ATTTTTTTTT CTTTTTAATA TTTTCTTCTG GTCACAAAAT	1616
AAAGAAATT GGGATGCAA GTACCTAAAG ATCTCTGATC CTAAGAAGTT ACTTCTGGCC	1676
AGGCGCGGTG GCTCATGCCT GTAATCCTAG CACTTTGGGA GGCTGAGGTA GGCAGATCAC	1736
TTGAGGTCAG GAGTTGGAGA CCAGCCTGGC CAACATAGTG AAACCCCGTC TCTACTAAAA	1796
ATGCAAAAAT TAGCCAGGCG TAGTGGTGGC CACCTGTAGT CTCAGATACT TGGGAGGCTG	1856
AGGGTGGAGA ATCGCTTGAA CCTGGGAGGT GGAGATTGCA GTGAGTCAAG ATCTCACCAC	1916
TGAACTCCAG CCTGGGCGAC AGAGGGAGAC TCTGTCTCAA AAAAAAAGAA GTTACTTCCA	1976
AGACAGACTT TTAACATGTA ACCAGCACAA AGCAATGTCA GGGAGGAGTG ATACATGACA	2036
ATAAATGAGT CAGATGAGCA AGAAGGCCCC AGAACCCATG CCCCAAGGCA CAAAGAGGAG	2096
CTCAGGGTAG GCCCAAAGAC TCGAATTCCT TAGATTACTA AATCACATGA GCGGACCTTG	2156
TCTGTCAGAT AAGATTTTTA CCTGGAAATT CCATGACCAA TACATGTGCA AAAGAAAATG	2216
ATGGGTTGAA TTTACTGATT ATTGACCTAA TGGATGGCTT TTTAAAATGT TTTAATAAAA	2276
AAGCAGAATA GATGTTTGT TTTCTAGTGG TTATACCAAG TTATACTTCC TGTTTTACAG	2336
TGTGAAAAGTA ACATGGGACA TGCCTTCTT TTCCGATCAG TTTATTTAAG CTATACAGCA	2396
AACTTTGGCA TTTATGTGGA GCATTTCTCA TTGTTGGAAT CTGAATAAAC CAATTACAAA	2456
ATAAAAAAAAAA AAAAAAAAAA A	2477

( 2 ) INFORMATION FOR SEQ ID NO:2:

- ( i ) SEQUENCE CHARACTERISTICS:
  - ( A ) LENGTH: 393 amino acids
  - ( B ) TYPE: amino acid
  - ( D ) TOPOLOGY: linear

( ii ) MOLECULE TYPE: protein

( xi ) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met	Trp	Trp	Arg	Val	Leu	Ser	Leu	Leu	Ala	Trp	Phe	Pro	Leu	Gln	Glu
1				5					10					15	
Ala	Ser	Leu	Thr	Asn	His	Thr	Glu	Thr	Ile	Thr	Val	Glu	Glu	Gly	Gln
			20					25					30		
Thr	Leu	Thr	Leu	Lys	Cys	Val	Thr	Ser	Leu	Arg	Lys	Asn	Ser	Ser	Leu
		35					40					45			
Gln	Trp	Leu	Thr	Pro	Ser	Gly	Phe	Thr	Ile	Phe	Leu	Asn	Glu	Tyr	Pro
	50					55					60				
Ala	Leu	Lys	Asn	Ser	Lys	Tyr	Gln	Leu	Leu	His	His	Ser	Ala	Asn	Gln
65					70					75				80	
Leu	Ser	Ile	Thr	Val	Pro	Asn	Val	Thr	Leu	Gln	Asp	Glu	Gly	Val	Tyr
				85					90					95	
Lys	Cys	Leu	His	Tyr	Ser	Asp	Ser	Val	Ser	Thr	Lys	Glu	Val	Lys	Val

-continued

100					105					110					
Ile	Val	Leu	Ala	Thr	Pro	Phe	Lys	Pro	Ile	Leu	Glu	Ala	Ser	Val	Ile
		115					120					125			
Arg	Lys	Gln	Asn	Gly	Glu	Glu	His	Val	Val	Leu	Met	Cys	Ser	Thr	Met
	130					135					140				
Arg	Ser	Lys	Pro	Pro	Pro	Gln	Ile	Thr	Trp	Leu	Leu	Gly	Asn	Ser	Met
145					150					155					160
Glu	Val	Ser	Gly	Gly	Thr	Leu	His	Glu	Phe	Glu	Thr	Asp	Gly	Lys	Lys
				165					170					175	
Cys	Asn	Thr	Thr	Ser	Thr	Leu	Ile	Ile	Leu	Ser	Tyr	Gly	Lys	Asn	Ser
			180					185					190		
Thr	Val	Asp	Cys	Ile	Ile	Arg	His	Arg	Gly	Leu	Gln	Gly	Arg	Lys	Leu
		195					200					205			
Val	Ala	Pro	Phe	Arg	Phe	Glu	Asp	Leu	Val	Thr	Asp	Glu	Glu	Thr	Ala
	210					215					220				
Ser	Asp	Ala	Leu	Glu	Arg	Asn	Ser	Leu	Ser	Thr	Gln	Asp	Pro	Gln	Gln
225					230					235					240
Pro	Thr	Ser	Thr	Val	Ser	Val	Thr	Glu	Asp	Ser	Ser	Thr	Ser	Glu	Ile
				245					250					255	
Asp	Lys	Glu	Glu	Lys	Glu	Gln	Thr	Thr	Gln	Asp	Pro	Asp	Leu	Thr	Thr
			260					265					270		
Glu	Ala	Asn	Pro	Gln	Tyr	Leu	Gly	Leu	Ala	Arg	Lys	Lys	Ser	Gly	Ile
		275					280					285			
Leu	Leu	Leu	Thr	Leu	Val	Ser	Phe	Leu	Ile	Phe	Ile	Leu	Phe	Ile	Ile
	290					295					300				
Val	Gln	Leu	Phe	Ile	Met	Lys	Leu	Arg	Lys	Ala	His	Val	Ile	Trp	Lys
305					310					315					320
Arg	Glu	Asn	Glu	Val	Ser	Glu	His	Thr	Leu	Glu	Ser	Tyr	Arg	Ser	Arg
				325					330					335	
Ser	Asn	Asn	Glu	Glu	Thr	Ser	Ser	Glu	Glu	Lys	Asn	Gly	Gln	Ser	Ser
			340					345					350		
Leu	Pro	Met	Arg	Cys	Met	Asn	Tyr	Ile	Thr	Lys	Leu	Tyr	Ser	Glu	Ala
		355					360					365			
Lys	Thr	Lys	Arg	Lys	Glu	Asn	Val	Gln	His	Ser	Lys	Leu	Glu	Glu	Lys
	370					375					380				
His	Ile	Gln	Val	Pro	Glu	Ser	Ile	Val							
385					390										

## ( 2 ) INFORMATION FOR SEQ ID NO:3:

## ( i ) SEQUENCE CHARACTERISTICS:

- ( A ) LENGTH: 1940 base pairs
- ( B ) TYPE: nucleic acid
- ( C ) STRANDEDNESS: single
- ( D ) TOPOLOGY: linear

## ( ii ) MOLECULE TYPE: cDNA

## ( ix ) FEATURE:

- ( A ) NAME/KEY: CDS
- ( B ) LOCATION: 31..1197

## ( xi ) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GGAAAAGCTCC CTCGTTTCAG CACAGCCAGC ATG TGG TGG GGA GTC CTC AGT TTG 54  
 Met Trp Trp Gly Val Leu Ser Leu  
 1 5

CTG TTC TGG GTG CCG GTG CAA GCA GCC TTT CTG AAA ATG GAG ACC GTC 102  
 Leu Phe Trp Val Pro Val Gln Ala Ala Phe Leu Lys Met Glu Thr Val  
 10 15 20

-continued

ACG Thr 25	GTA Val	GAG Glu	GAA Glu	GGC Gly	CAA Gln 30	ACG Thr	CTC Leu	ACT Thr	CTA Leu	ACG Thr 35	TGT Cys	GTT Val	ACT Thr	TCT Ser	CAG Gln 40	150
ACA Thr	AAA Lys	AAC Asn	GTC Val	TCT Ser 45	CTC Leu	CAG Gln	TGG Trp	CTG Leu	GCT Ala 50	CCC Pro	TCT Ser	GGG Gly	TTC Phe	ACC Thr 55	ATT Ile	198
TTT Phe	TTA Leu	AAC Asn	CAG Gln 60	CAT His	CCT Pro	GCT Ala	TTA Leu	AAA Lys 65	AGC Ser	TCC Ser	AAA Lys	TAC Tyr	CAG Gln 70	CTT Leu	CTT Leu	246
CAC His	CAT His	TCA Ser 75	GCT Ala	ACA Thr	CAA Gln	CTC Leu	TCC Ser 80	ATT Ile	AGT Ser	GTG Val	TCC Ser	AAT Asn 85	GTA Val	ACT Thr	CTC Leu	294
CGA Arg	GAG Glu 90	GAA Glu	GGT Gly	GTG Val	TAT Tyr	ACA Thr 95	TGC Cys	TTG Leu	CAC His	TAC Tyr	GGG Gly 100	AGT Ser	TCT Ser	GTG Val	AAG Lys	342
ACG Thr 105	AAG Lys	CAA Gln	GTG Val	AGA Arg 110	GTG Val	ACC Thr	GTG Val	TTA Leu	GTG Val	ACT Thr 115	CCT Pro	TTC Phe	CAG Gln	CCA Pro	ACC Thr 120	390
GTG Val	GAA Glu	GCT Ala	TTG Leu	GTT Val 125	CTC Leu	AGA Arg	AGG Arg	CAG Gln	AAT Asn 130	GGA Gly	GAG Glu	AAA Lys	TCT Ser	GTT Val 135	GTG Val	438
CTG Leu	AAA Lys	TGT Cys	TCC Ser 140	ACA Thr	GAG Glu	AGA Arg	AGC Ser	AAG Lys 145	CCC Pro	CCG Pro	CCA Pro	CAA Gln	ATC Ile 150	ACC Thr	TGG Trp	486
CTG Leu	CTG Leu	GGG Gly 155	GAA Glu	GGT Gly	CTG Leu	GAG Glu	ATC Ile 160	TAT Tyr	GGT Gly	GAA Glu	CTC Leu	CAC His 165	CAT His	GAA Glu	TTT Phe	534
GAA Glu 170	GCT Ala	GAT Asp	GGG Gly	AAA Lys	ATA Ile	TGT Cys 175	AAC Asn	ACC Thr	AGC Ser	AGC Ser	ACG Thr 180	CTC Leu	ATC Ile	GCC Ala	CGC Arg	582
GCG Ala 185	TAC Tyr	GGC Gly	AAA Lys	AAC Asn	TCA Ser 190	ACC Thr	GTG Val	CAC His	TGC Cys	ATT Ile 195	ATC Ile	CAG Gln	CAC His	GAG Glu	GGC Gly 200	630
TTG Leu	CAC His	GGG Gly	AGA Arg	AAG Lys 205	CTG Leu	GTT Val	GCC Ala	CCC Pro	TTC Phe 210	CAG Gln	TTT Phe	GAA Glu	GAT Asp	TTG Leu 215	GTT Val	678
GCA Ala	GAT Asp	CAA Gln	GAA Glu 220	ACG Thr	ACT Thr	TCA Ser	GAT Asp 225	GCC Ala	CCT Pro	GAG Glu	CAG Gln	AGC Ser	TCT Ser 230	CTC Leu	TCC Ser	726
TCC Ser	CAA Gln 235	GCC Ala	CTC Leu	CAG Gln	CAG Gln	CCC Pro	ACA Thr 240	AGT Ser	ACA Thr	GTC Val	TCA Ser	ATG Met 245	ATG Met	GAA Glu	AAT Asn	774
TCC Ser 250	AGT Ser	ATA Ile	CCA Pro	GAG Glu	ACT Thr	GAC Asp 255	AAG Lys	GAA Glu	GAG Glu	AAA Lys 260	GAA Glu	CAT His	GCC Ala	ACT Thr	CAA Gln	822
GAC Asp 265	CCT Pro	GGC Gly	TTG Leu	TCC Ser	ACT Thr 270	GCC Ala	AGT Ser	GCT Ala	CAG Gln	CAT His 275	ACA Thr	GGA Gly	CTG Leu	GCC Ala	CGG Arg 280	870
AGG Arg	AAG Lys	AGT Ser	GGT Gly	ATC Ile 285	CTG Leu	CTG Leu	CTC Leu	ACG Thr	CTG Leu	GTG Val 290	TCC Ser	TTC Phe	CTC Leu	ATT Ile 295	TTC Phe	918
ATC Ile	CTT Leu	TTC Phe	ATC Ile 300	ATC Ile	GTT Val	CAG Gln	CTC Leu	TTC Phe 305	ATC Ile	ATG Met	AAG Lys	CTG Leu	CGT Arg 310	AAA Lys	GCA Ala	966
CAC His	GTG Val 315	GTA Val	TGG Trp	AAG Lys	AAG Lys	GAA Glu	AGT Ser 320	GAA Glu	ATT Ile	TCA Ser	GAG Glu	CAA Gln 325	GCT Ala	CTA Leu	GAA Glu	1014
AGT Ser 330	TAC Tyr	AGA Arg	TCA Ser	AGA Arg	TCC Ser	AAC Asn 335	AAC Asn	GAG Glu	GAG Glu	ACA Thr	TCT Ser	TCC Ser	CAG Gln	GAG Glu	AAT Asn	1062

-continued

AGC	AGC	CAG	GCT	CCC	CAG	TCT	AAG	CGT	TGC	ATG	AAC	TAC	ATC	ACG	CAG	1110
Ser	Ser	Gln	Ala	Pro	Gln	Ser	Lys	Arg	Cys	Met	Asn	Tyr	Ile	Thr	Gln	
345					350					355					360	
TTA	TAC	TCG	GGA	GCC	AAA	ACA	AAG	AAG	AGT	GCC	CAG	CAC	TGG	AAG	CTC	1158
Leu	Tyr	Ser	Gly	Ala	Lys	Thr	Lys	Lys	Ser	Ala	Gln	His	Trp	Lys	Leu	
				365					370						375	
GGA	GGC	AAG	CAC	AGC	CGT	GTC	CCG	GAG	AGT	ATT	GTG	TAGTGTTC				1204
Gly	Gly	Lys	His	Ser	Arg	Val	Pro	Glu	Ser	Ile	Val					
			380					385								
TGCAATAGAA	GATAGGATTT	CAGGGCAGCC	GCATCAGGCC	CTGGAAAGGA	TCGTAAGTAC											1264
TGTGACATGA	AAAAAATAGA	ATGTCCATTG	AGTACAATTC	AAGACAGTGT	CCATTGAGCC											1324
AGGGCAGCCA	CATGAGGACC	AAGCCATGGA	CAGAAAGCTC	CTCGCTGAAA	GGAAAACATA											1384
GAAAGAACCT	ATTATGACTG	ACACTACCTC	AGAGCTGGAG	AACTCTGCTA	AGTCGTTTTG											1444
GATCAGGGTC	AAAATGACCA	GTGAGCAGCT	GACCTCGAAG	GGAACAGCTT	TTTAGACCTG											1504
GGGCTGGAGT	GGAAGTGTTC	GAATTGGTTT	AAAATCTTTC	CTTCTCGGTC	AAGAAGAACT											1564
TAAGCAGAGA	AGTACCCCAA	GGAGACCTGA	GATGCCAGCA	GCCTGCTTTC	AAGACAGCCT											1624
CTCAGAAGAG	GCCTGGTGGG	CAACAGAGAA	ATGTGGGCTG	TTACAGCACA	CAGTGAACAT											1684
GATGCCTCCC	AGAGAGCTAC	AACTCTCAAC	TGAGTTCAAC	TGACAAGAGG	CTTCCTGACT											1744
AACCATGAGC	CAACCTGACA	GGCCACTTTT	ATCCTAATTA	CACCATGGTA	AAAGTAGGGA											1804
CAGAAGCAAA	CTGTGAGTTT	GGTTGACAGA	CTGTTGAATT	TGTGACTGGC	TTTTAGAATT											1864
TTAATAAAGA	CCAGAATGTG	TCTTTTTAGA	GGCTGTCATG	CCCATTGATA	AAAAAAAAAA											1924
AAAAAAAAAA	AAAAAA															1940

( 2 ) INFORMATION FOR SEQ ID NO:4:

- ( i ) SEQUENCE CHARACTERISTICS:
  - ( A ) LENGTH: 388 amino acids
  - ( B ) TYPE: amino acid
  - ( D ) TOPOLOGY: linear

( ii ) MOLECULE TYPE: protein

( xi ) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met	Trp	Trp	Gly	Val	Leu	Ser	Leu	Leu	Phe	Trp	Val	Pro	Val	Gln	Ala	
1				5					10					15		
Ala	Phe	Leu	Lys	Met	Glu	Thr	Val	Thr	Val	Glu	Glu	Gly	Gln	Thr	Leu	
			20					25					30			
Thr	Leu	Thr	Cys	Val	Thr	Ser	Gln	Thr	Lys	Asn	Val	Ser	Leu	Gln	Trp	
		35					40					45				
Leu	Ala	Pro	Ser	Gly	Phe	Thr	Ile	Phe	Leu	Asn	Gln	His	Pro	Ala	Leu	
	50					55					60					
Lys	Ser	Ser	Lys	Tyr	Gln	Leu	Leu	His	His	Ser	Ala	Thr	Gln	Leu	Ser	
65					70					75					80	
Ile	Ser	Val	Ser	Asn	Val	Thr	Leu	Arg	Glu	Glu	Gly	Val	Tyr	Thr	Cys	
				85					90					95		
Leu	His	Tyr	Gly	Ser	Ser	Val	Lys	Thr	Lys	Gln	Val	Arg	Val	Thr	Val	
			100					105					110			
Leu	Val	Thr	Pro	Phe	Gln	Pro	Thr	Val	Glu	Ala	Leu	Val	Leu	Arg	Arg	
		115					120					125				
Gln	Asn	Gly	Glu	Lys	Ser	Val	Val	Leu	Lys	Cys	Ser	Thr	Glu	Arg	Ser	
	130					135						140				
Lys	Pro	Pro	Pro	Gln	Ile	Thr	Trp	Leu	Leu	Gly	Glu	Gly	Leu	Glu	Ile	
145				150						155					160	

-continued

Tyr	Gly	Glu	Leu	His	His	Glu	Phe	Glu	Ala	Asp	Gly	Lys	Ile	Cys	Asn
				165					170					175	
Thr	Ser	Ser	Thr	Leu	Ile	Ala	Arg	Ala	Tyr	Gly	Lys	Asn	Ser	Thr	Val
			180					185					190		
His	Cys	Ile	Ile	Gln	His	Glu	Gly	Leu	His	Gly	Arg	Lys	Leu	Val	Ala
		195					200					205			
Pro	Phe	Gln	Phe	Glu	Asp	Leu	Val	Ala	Asp	Gln	Glu	Thr	Thr	Ser	Asp
	210					215					220				
Ala	Pro	Glu	Gln	Ser	Ser	Leu	Ser	Ser	Gln	Ala	Leu	Gln	Gln	Pro	Thr
225					230				235						240
Ser	Thr	Val	Ser	Met	Met	Glu	Asn	Ser	Ser	Ile	Pro	Glu	Thr	Asp	Lys
				245				250						255	
Glu	Glu	Lys	Glu	His	Ala	Thr	Gln	Asp	Pro	Gly	Leu	Ser	Thr	Ala	Ser
			260					265					270		
Ala	Gln	His	Thr	Gly	Leu	Ala	Arg	Arg	Lys	Ser	Gly	Ile	Leu	Leu	Leu
		275					280					285			
Thr	Leu	Val	Ser	Phe	Leu	Ile	Phe	Ile	Leu	Phe	Ile	Ile	Val	Gln	Leu
	290					295					300				
Phe	Ile	Met	Lys	Leu	Arg	Lys	Ala	His	Val	Val	Trp	Lys	Lys	Glu	Ser
305					310					315					320
Glu	Ile	Ser	Glu	Gln	Ala	Leu	Glu	Ser	Tyr	Arg	Ser	Arg	Ser	Asn	Asn
				325					330					335	
Glu	Glu	Thr	Ser	Ser	Gln	Glu	Asn	Ser	Ser	Gln	Ala	Pro	Gln	Ser	Lys
			340					345					350		
Arg	Cys	Met	Asn	Tyr	Ile	Thr	Gln	Leu	Tyr	Ser	Gly	Ala	Lys	Thr	Lys
		355					360					365			
Lys	Ser	Ala	Gln	His	Trp	Lys	Leu	Gly	Gly	Lys	His	Ser	Arg	Val	Pro
	370					375					380				
Glu	Ser	Ile	Val												
385															

40

What is claimed is:

1. An antibody or an antigen binding portion thereof which specifically binds to a recombinant or purified primate CRTAM, Cytotoxic or Regulatory T cell Associated Molecule, protein.

2. A conjugate comprising an antibody or antigen binding portion thereof which binds to a primate CRTAM, Cytotoxic or Regulatory T cell Associated Molecule.

3. The conjugate of claim 2, wherein said primate is a human.

4. A kit comprising said conjugate of claim 2.

5. The conjugate of claim 2, comprising an antibody.

6. The antibody or antigen binding portion of claim 1, wherein said primate is human.

7. The conjugate of claim 2, wherein said antibody is produced by immunizing an animal with a purified or recombinant polypeptide comprising a sequence of SEQ ID NO: 2 or 4.

8. The conjugate of claim 2, wherein said antibody is from mouse, rat, or human.

9. The conjugate of claim 2, wherein said antibody is a monoclonal antibody.

10. The conjugate of claim 2, wherein said antibody or antigen binding portion is labeled.

11. The conjugate of claim 10, wherein said label is selected from the group consisting of:

a) radioactive;

b) fluorescent;

c) chemiluminescent; and

d) magnetic.

12. The kit of claim 4, wherein said conjugate comprises a label.

13. The kit of claim 4, further comprising instructions for using or disposing of reagents of said kit.

14. The kit of claim 4, further comprising a substantially pure CRTAM protein or peptide thereof capable of binding said conjugate.

15. The kit of claim 4, in a format for:

a) radioimmunoassay (RIA);

b) enzyme-linked immunosorbent assay (ELISA);

c) enzyme immunoassay (EIA);

d) enzyme-multiplied immunoassay technique (EMIT); or

e) substrate-labeled fluorescent immunoassay (SLFIA).

16. An immunoabsorbent matrix comprising a conjugate of claim 2.

17. The conjugate of claim 2, which exhibits a  $K_D$  for human CRTAM of at least about 10  $\mu$ M.

18. The conjugate of claim 2, wherein said antibody or antigen binding portion is coupled to a toxin or drug.

19. The antibody or antigen binding portion of claim 1, which binds to a protein of SEQ ID NO: 2 or 4.

20. The conjugate of claim 2, which binds to a protein of SEQ ID NO: 2 or 4.



21. The antibody or antigen binding portion of claim 19, which binds to a mouse CRTAM of SEQ ID NO: 4.

22. The antibody or antigen binding portion of claim 1, wherein said antibody is produced by immunizing an animal with a purified or recombinant protein of SEQ ID NO: 2 or 4.

23. The conjugate of claim 2, wherein said antibody is produced by immunizing an animal with a purified or recombinant human CRTAM.

24. The conjugate of claim 2, wherein said conjugate is sterile.

25. A method of making an antibody of claim 1, comprising the step of immunizing an animal with a primate CRTAM protein, thereby inducing said animal to produce said antibody.

26. The method of claim 25, wherein said primate CRTAM consists of amino acid sequence in SEQ ID NO: 2.

27. A method of purifying a mammalian CRTAM protein comprising the steps of contacting said protein with an antibody or antigen binding portion of claim 1, thereby specifically forming a CRTAM:antibody or CRTAM:antigen binding portion complex; separating said complex from unbound substances; and separating said CRTAM from said complex.

28. A method of identifying a population of CRTAM-bearing cells comprising the steps of contacting said cells with a labeled conjugate of claim 11 and distinguishing labeled cells from unlabeled cells.

\* \* \* \* \*